Global  Clin
ical Development  - General  Medicine  
Secukinumab (AIN457) 
Clinical
 Trial Protocol CAIN457A2311 / [STUDY_ID_REMOVED]
A randomized, open-l abel, multicenter trial to assess the 
efficacy of subcutaneous secukinumab after twelve weeks 
of treatment, and to assess the long-term s afety, 
tolerability and efficacy in subjects from 6 to less than 18 
years of age with moderate to severe chronic plaque 
psoriasis 
Document type:  Amended Protocol  Version 
EUDRACT number:  2017- 004515- 39 
Version number:  01 (Amendment  1) Clean 
Clinical trial phase:  III 
Release date:  25-Sep-2020
Property  of Novartis 
Confidential  
May not be used,  divulged,  published,  or otherwise disclosed 
without the consent of Novartis  
Clinical Trial  Protocol Template  Version 3.4 (May  2017)  

Novartis  Confidential  Page  2 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Table of contents  
Table  of contents  .................................................................................................................. 2 
List of tables ......................................................................................................................... 6 
List of figures  ....................................................................................................................... 6 
List of abbreviations  ............................................................................................................. 7 
Glossary  of terms  ............................................................................................................... 10 
Amendment 1 (25- Sep-2020)  .................................................................................................... 11 
Protocol summary  .............................................................................................................. 13 
 Introduction  ........................................................................................................................ 16 
1.1 Background  ............................................................................................................ 16 
1.2 Purpose  ................................................................................................................... 18 
 Study objectives and endpoints  .......................................................................................... 19 
2.1 Objectives and related  endpoints  ............................................................................ 19 
 Investigational plan ............................................................................................................ 20 
3.1 Study design  ........................................................................................................... 20 
3.2 Rationale for study design ...................................................................................... 22 
3.3 Rationale for dose/regimen, route of administration  and duration of treatment  ..... 23 
3.4 Rational for choice of comparator  .......................................................................... 24 
3.5 Purpose and timing  of interim  analyses/design  adaptations  ................................... 24 
3.6 Risks  and benefits  .................................................................................................. 24 
 Population  .......................................................................................................................... 25 
4.1 Inclusion criteria  ..................................................................................................... 25 
4.2 Exclusion criteria  ................................................................................................... 26 
 Treatment  ........................................................................................................................... 28 
5.1 Study treatment  ...................................................................................................... 28 
5.1.1 Investigational and control drugs  ........................................................... 28 
5.1.2 Additional treatment  .............................................................................. 28 
5.2 Treatment  arms ....................................................................................................... 28 
5.3 Treatment  assignment  and randomization  .............................................................. 29 
5.4 Treatment  blinding  ................................................................................................. 30 
5.5 Treating  the subject  ................................................................................................ 30 
5.5.1 Subject numbering  ................................................................................. 30 
5.5.2 Dispensing the study drug ..................................................................... 31 
5.5.3 Handling of study and additional treatment  ........................................... 32 
5.5.4 Instructions  for prescribing and taking  study treatment  ......................... 32 
5.5.5 Permitted  dose adjustments  and interruptions of study treatment .......... 33 

Novartis  Confidential  Page  3 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
5.5.6 Rescue medication  ................................................................................. 33 
5.5.7 Prior and Concomitant medication  ........................................................ 33 
5.5.8 Prohibited medication  ............................................................................ 35 
5.5.9 Emergency  breaking of assigned  treatment code ................................... 36 
5.6 Study completion and discontinuation  ................................................................... 36 
5.6.1 Study completion and post-study treatment  ........................................... 36 
5.6.2 Discontinuation of study treatment ........................................................ 37 
5.6.3 Withdrawal  of informed  consent  ........................................................... 38 
5.6.4 Loss  to follow -up ................................................................................... 38 
5.6.5 Early  study termination  by the sponsor  ................................................. 39 
 Visit schedule and assessments .......................................................................................... 39 
6.1 Information  to be collected  on screening  failures  .................................................. 47 
6.2 Subject demographics/other baseline characteristics .............................................. 47 
6.2.1 Demographics  ........................................................................................ 47 
6.2.2 Psoriasis  medical  history  / Previous psoriasis  therapy  ........................... 47 
6.2.3 Relevant  medical  history  / current medical  conditions  .......................... 47 
6.2.4 Determination  of Tuberculosis status .................................................... 48 
6.2.5 Other  baseline characteristics ................................................................ 51 
6.3 Treatment  exposure and compliance  ...................................................................... 51 
6.4 Efficacy  .................................................................................................................. 51 
6.4.1 Investigator Global assessment  (IGA  mod 2011)  .................................. 51 
6.4.2 Assessment  of total body surface area (BSA)  and psoriasis  area 
safety  index (PASI)  ............................................................................... 52 
  54 
6.4.4 Appropriateness of efficacy  assessments ............................................... 54 
6.5 Safety  ..................................................................................................................... 55 
6.5.1 Physical  examination  ............................................................................. 55 
  55 
6.5.3 Vital signs  .............................................................................................. 56 
6.5.4 Height and weight  .................................................................................. 56 
6.5.5 Laboratory evaluations  .......................................................................... 56 
6.5.6 Electrocardiogram  (ECG)  ...................................................................... 58 
6.5.7 Immunogenicity ..................................................................................... 58 
6.5.8 Pregnancy and assessments of fertility  .................................................. 59 
6.5.9 Appropriateness of safety  measurements ............................................... 60 
6.6 Other  assessments .................................................................................................. 60 

Novartis  Confidential  Page  4 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.6.1 Clinical Outcome Assessments (COAs)  ................................................ 60 
6.6.2 Resource utilization  ............................................................................... 61 
6.6.3 Pharmacokinetics ................................................................................... 62 
6.6.4 Other  biomarkers  ................................................................................... 62 
 Safety  monitoring  ............................................................................................................... 62 
7.1 Adverse events  ....................................................................................................... 62 
7.2 Serious adverse events  ........................................................................................... 64 
7.2.1 Definition  of SAE .................................................................................. 64 
7.2.2 SAE  reporting  ........................................................................................ 65 
7.3 Liver  safety  monitoring  .......................................................................................... 66 
7.4 Renal  safety  monitoring  ......................................................................................... 66 
7.5 Reporting of study treatment errors  including misuse/abuse  .................................. 66 
7.6 Pregnancy reporting  ............................................................................................... 67 
 Data  review  and database  management  ............................................................................. 67 
8.1 Site monitoring  ....................................................................................................... 67 
8.2 Data  collection  ....................................................................................................... 68 
8.3 Database management  and quality  control  ............................................................. 68 
8.4 Data  Monitoring  Committee  .................................................................................. 69 
8.5 Adjudication Committee  ........................................................................................ 69 
 Data  analysis ...................................................................................................................... 69 
9.1 Analysis sets ........................................................................................................... 69 
9.2 Subject demographics and other baseline characteristics ....................................... 70 
9.3 Treatments  .............................................................................................................. 70 
9.4 Analysis of the primary  variable(s)  ........................................................................ 70 
9.4.1 Primary  Variable(s)  ............................................................................... 71 
9.4.2 Statistical model, hypothesis, and method of analysis  ........................... 71 
9.4.3 Handling of missing  values/censoring/discontinuations  ........................ 71 
9.4.4 Sensitivity  analyses  ................................................................................ 72 
9.5 Analysis of secondary  variables  ............................................................................. 72 
9.5.1 Efficacy  variables  .................................................................................. 72 
9.5.2 Safety  variables  ...................................................................................... 72 
9.5.3 Resource utilization  ............................................................................... 74 
9.5.4 Health -Related  Quality  of Life .............................................................. 74 
9.5.5 Pharmacokinetics ................................................................................... 74 
9.5.6 DNA  ...................................................................................................... 74 
9.5.7 Biomarkers  ............................................................................................ 74 

Novartis  Confidential  Page  5 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
9.5.8 PK/PD  .................................................................................................... 74 
9.6 Analysis of exploratory variables  ........................................................................... 74 
9.7 Interim analyses  ..................................................................................................... 75 
9.8 Sample  size calculation  .......................................................................................... 75 
 Ethical considerations  ........................................................................................................ 76 
10.1 Regulatory and ethical  compliance  ........................................................................ 76 
10.2 Informed  consent  procedures  ................................................................................. 77 
10.3 Responsibilities of the investigator and IRB/IEC  .................................................. 78 
10.4 Publication  of study protocol and results  ............................................................... 78 
10.5 Quality  Control and Quality  Assurance .................................................................. 78 
 Protocol adherence  ............................................................................................................. 78 
11.1 Protocol amendments  ............................................................................................. 79 
 References  .......................................................................................................................... 80 
 Appendix 1: Clinically notable laboratory parameters  ...................................................... 83 
 Appendix 2: Blood collection log for pharmacokinetics and immunogenicity ................. 85 
 86 
 Appendix 4: Weight and recommended blood volumes .................................................... 87 

Novartis  Confidential  Page  6 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
List of tables  
Table  2-1 Objectives and related endpoints  ........................................................... 19 
Table  5-1 Number of injections per visit per treatment arm .................................. 29 
Table  5-2 Disease severity  classification  ............................................................... 30 
Table  5-3 Prohibited medication  ............................................................................ 35 
Table  6-1 Assessment  schedule (Year  1) ............................................................... 41 
Table  6-2 Assessment  schedule - Years 2-4 (continued)  ....................................... 44 
Table  6-3 IGA mod 2011 scale  .............................................................................. 52 
Table  6-4 PASI  scoring  system  .............................................................................. 53 
Table  6-5 Recommended  Dimensions  for Blood Pressure Cuff Bladders  ............. 56 
Table 7 -1 Guidance for capturing the study treatment errors including 
misuse/abuse .......................................................................................... 66 
Table  9-1 Treatment groups for analyses  .............................................................. 69 
Table  9-2 Predictive placebo response rates for this study  from model of  
historical data ........................................................................................ 76 
Table  14-1 Blood collection  log for pharmacokinetics  ............................................ 85 
Table  14-2 Blood Collection  for Immunogenicity ................................................... 85 
Table 16-1 Total blood volume, 1% and 3% of total blood volume by weight 
assuming 85mL per kg total blood volume ........................................... 87 
List of figures  
Figure 3-1 Study design  .......................................................................................... 20 
Figur
e 3-2 Average concentration for the proposed low dose and high dose 
secukinumab arms  ................................................................................. 23 
Figure 6-1 Tuberculosis screening  flowchart  .......................................................... 50 

Novartis  Confidential  Page  7 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
List of abbreviations  
AE Adverse  Event  
ALP Alkaline  Phosphatase 
ALT Alanine Aminotransferase 
AST Aspartate  Aminotransferase 
ATC Anatomical  Therapeutic  Chemical  
BDR Bioanalytical  Data  Report  
BP Blood Pressure  
BSA Body  Surface  Area 
BUN Blood Urea  Nitrogen  
CDLQI  Children’s  Dermatology  Life Quality  Index  
COVID -19 Coronavirus  disease of 2019  
CFR Code  of Federal  Regulations  
CRF Case  Report/Record Form  (paper  or electronic)  
CPO  Country  Pharma  Organization 
CRO  Contract  Research Organization  
CS Corticosteroid  
CTC Common Toxicity  Criteria 
DMC  Data  Monitoring Committee  
DS & E Drug  Safety  and Epidemiology  
ECG  Electrocardiogram  
EDC Electronic  Data  Capture  
eCRF  Electronic  Case  Report/Record Form  
eg Example  
eGFR  estimated Glomerular  Filtration  Rate 
EMA European Medical  Association 
EOT End of Treatment  
EOF End of Follow -up 
EU European Union 
FAS Full Analysis  Set 
FDA Food and Drug  Administration  
GCP  Good Clinical  Practice  
GGT  Gamma  –glutamyl  transferase 
hCG Human  chorionic  gonadotropin 
HIV Human  Immunodeficiency  Virus  
HrQoL Health -related Quality  of Life 
IB Investigator  Brochure  
ICF Informed Consent  Form 
ICH International  Council  for Harmonization of Technical  Requirements  for 
Registration of Pharmaceuticals for Human Use  
IEC Independe nt Et hics Committee  
IG Immunogenicity  
IGA Investigator  Global  Assessment  

Novartis  Confidential  Page  8 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
 
IgG Immunoglobulin G 
IL Interleukin  
IQS Integrated Quantitative Sciences  
IRB Institutional  Review  Board 
IRT Interactive  Response  Technology  
IN Investigator  Notification  
IUD Intrauterine Device  
IUS Intrauterine System  
LLN Lower  Limit  of Normal  
LOCF  Last Observation Carried Forward  
MACE Major  Adverse  Cardiovascular  Events  
MAP Meta -analytical -prediction  
MedDRA  Medical  dictionary  for regulatory  activities  
MI Myocardial  Infarction  
PASI  Psoriasis  Area  and Severity  Index  
PDCO  Pediatric  Committee  of the European Medicines  Agency  
PPD Purified  Protein  derivative  
PFS Pre-filled syringe 
PK pharmacokinetic  
PRO  Patient  reported outcom e 
PS Patient  Sa
fety 
PUVA  Photochemotherapy  (eg psoralen  + UVA treatment)  
QFT QuantiFERON  TB-Gold test 
QM Quality  Management  
R Randomization 
rpm Rate  per minute  
SAE Serious  Adverse  Event  
SAP Statistical  Analysis  Plan 
sc subcutaneous  
SGOT  Serum  glutamic  oxaloacetic  transaminase 
SGPT  Serum  glutamic  pyruvic  transaminase 
SST Serum  Separator Tube  
SUSAR  Suspected Unexpected Serious  Adverse Reaction  
TB tuberculosis  
TBL Total  Bilirubin  
TCS Topical  corticosteroids  
Th17 T helper  17 cells 
ULN Upper  Limit  of Normal  
UV Ultraviolet  
UVA Ultrav i olet A, long wave  400 nm–315 nm 
UVB Ultraviolet  B, medium  wave  315 nm–280 nm 
Vs Versus  
WBC  White  blood cells / leukocytes  

Novartis  Confidential  Page  9 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
 
WHO  World  Health  Organization  
WoC  Withdrawal  of Consent  

Novartis  Confidential  Page  10 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Glossary of terms  
 
Cohort  A specific  group  of subjects/subjects  fulfilling  certain  criteria  
Historical control 
drug Drugs(s) used  from historical  data to act as a comparator  to evaluate 
comparative effects of the investigational drug  
Dosage  Dose  of the study  treatment  given to the subject  in a time unit (eg 100 mg once 
a day, 75 mg twice a day)  
Electronic  Data 
Capture (EDC) Electronic  data capture (EDC) is the electronic  acquisition of clinical  study  data 
using data collection systems, such as Web -based applications, interactive 
voice response systems and clinical laboratory interfaces.  
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used  to capture data transcribed from paper  source  forms  used  at the point  of 
care.  
Enrollment  Point/time of subject entry into the study at which informed consent must be 
obtained  (eg prior to starting  any of the procedures  described  in the protocol)  
Investigational 
drug The drug whose  properties  are being tested  in the study;  this definition  is 
consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug” or “investigational medicinal product.”  
Medication pack 
number  A unique identifier  on the label  of each  investigational  drug package  
Subject/subject 
ID A unique number  assigned  to each subject  upon signing  the informed consent  
Period  The subdivisions  of the trial design (eg Screening,  Treatment,  Follow -up) which  
are described in the Protocol.  Periods  define  the study  phases  and will be used 
in clinical trial database setup and eventually in analysis  
Randomization 
number  A unique identifier assigned  to each  randomized subject,  corresponding to a 
specific treatment arm assignment  
Source Data/Document  Source data refers  to the initial  record,  document,  or primary  location  from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource.  
Study  drug/ 
treatment  Any single  drug or combination  of drugs  administered  to the subject  as part of 
the required study  procedures;  includes  investigational  drug (s), 
placebo/comparator active drug run -ins or background therapy  
Study  Treatment 
Discontinuation 
(TD) When  the subject  permanently  stops  taking  study  treatment  prior to the defined 
study treatment completion date 
Variable  A measured value or assessed response that is determined in specific assessments  and used  in data analysis  to evaluate the drug being tested in the 
study  
Withdrawal  of 
study  consent 
(WoC)  Withdrawal of consent from the study is defined as when a subject does not want to participate in the study any longer, and does not want any  further visits 
or assessments,  and does  not want  any further  study  related contact,  and does 
not allow analysis of  already obtained biologic material  

Novartis  Confidential  Page  11 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Amendment  1 (25-Sep- 2020) 
Amendment  rationale  
The rationale for the amendment is to introduce a level of flexibility in drug dispensation, 
protocol assessment and visit schedule if a major health care event requires it (i.e. COVID -19 
pandemic) allowing patients to remain in the trial and  continue trea tment while being 
monitored for safety.  
The purpose of these changes is to reduce the risk of exposure for patients and site staff and potentially the risk of transmission of infectious diseases (e.g. COVID -19). 
These changes are  limited  to the duration of  COVID-19 pandemic or of any other major health 
care event and must be done in accordance with the local rules and regulations relevant to pandemic containment measures.  
Further to the above, minor  corrections,  clarifications  and editorial changes were  undertaken  in 
the protocol. 
Changes to the protocol:  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
The Amendment includes changes:  
• Due to COVID-19 pandemic or any other pandemic  
• Allowing  shipment of study medication to patient's home ( Section 5.5.2) 
• Alternative  options visits  (Sections 6, 6.5, 7.1) 
• Local  laboratory  testing  for safety  purposes ( Section  6.5.5) 
• Home  Pregnancy  testing (Section 6.5.8) 
• Remote  PRO collection  (Section 6.6.1.1) 
• Informed  Consent Form  (Section  10.2) 
• Home  Nursing Informed  Consent Form  (Section  10.2) 
• Significant Update to Original Protocol:  
• Added Inflammatory  Bowel  Disease as an example for discontinuation ofstudy 
treatment (Section 5.6.2 ). 
• ICF (Section  10.2) 
• To manage inconsistencies and provide clarifications  in the original protocol  
• clarify  prior medication ( S
 ection  5.5.7) 
• correct  data collection  to source only (weight in IRT, Table  6-1; Table  6-2) 
• Imputation  method ( Section  9.4.3) 
• Remove sensitivity  analysis ( Section  9.4.4) 
• Add growth/weight  to Safety  Section  9.5.2  
• As well as other  miscellaneous minor  corrections, modifications  and text adjustments  
• Modification  in Protocol summary  secondary objectives. 

Novartis  Confidential  Page  12 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
• Modification  in footnote 13 of Table  6-1. 
• Modification  in Urine  pregnanacy test, weight in IRT and footnote 10 
in Table 6 -2. 
• Modification in Section 9.5.4. 
• Modification in Section 9.6. 
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
This protocol amendment is considered substantial. However many countries participating in this study have released Urgent Safety Measure guidance stating that certain changes to a protocol due to the COVID -19 pandemic are permissible by  notification or by non- substantial 
amendment. Therefore the final determination of the protocol classification will be done on a country by country basis based on the latest local HA guidance. 
COVID-19 related  measures may/will be implemented  immediately  and prior to IRB/IE C and 
HA approvals. Submission for review and approval to IRB/IEC and Health Authorities should 
occur as early as possible.The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment . 

Novartis  Confidential  Page  13 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Protocol  summary  
Protocol  number  CAIN457A2311  
Full Title A randomized, open- label, multicenter trial to assess the efficacy of SC 
Secukinumab  after twelve weeks  of treatment,  and to assess  the long- term safety, 
tolerability and  efficacy in subjects from 6 to less than 18 years of age with 
moderate to severe chro nic plaque psoriasis  
Brief  title Study  to assess  the efficacy,  safety,  tolerability  and PK of secukinumab  in subjects 
6 to less than 18 years of age with moderate to severe chronic plaque psoriasis  
Sponsor  and Clinical 
Phase Novartis 
Phase  III 
Investigation  type Drug  
Study  type Interventional  
Purpose  and rationale  The purpose of this study is to assess the efficacy of secukinumab at  Week 12, 
based on both Psoriasis Area and Severity Index (PASI) 75 and Investigator’s 
Global Assessment (IGA) mod 2011 0 or 1 response rates in children and 
adolescents  aged  6 to less than 18 years  at randomization  with moderate  to severe 
chronic plaque psoriasis who are candidates for systemic therapy.  
This study will provide efficacy, safety and pharmacokinetic data to support the 
extension of label  of secukinumab  to include  children and adolescents  (6 years  to 
< 18 years)  with moderate  to severe  chronic  plaque  psoriasis.  
The study will assess the long -term efficacy, safety and tolerability of 
secukinumab over a period of up to 4 years to support the long -term use of 
secukinumab i n pediatric patients.  
Primary  Objective(s)  To evaluate  the ef ficacy  of secukinumab  in pediatric  subjects  aged  6 years  to less 
than 18 years  old with moderate  to severe  chronic  plaque  psoriasis  with respect  to 
PASI  75 and IG
A mod 2011  0 or 1 response  (co-primary  endpoints)  at Week  12, 
compared  to placebo  (historical  control).  
Secondary  Objectives  Objective  1: To eval uate the efficacy  of secukinumab in pediatric  subjects  aged  6 
years to less than 18 years old with moderate to severe chronic plaque psoriasis with respect to PAS
I 90 at Week 12, compared to placebo (historical control).  
Objective 2: To investigate the clinical safety and tolerability of secukinumab as assessed by 
growth, weight gain, vital signs, clinical laboratory variables, 
Electrocardiogram and AE monitoring  
Objective  3: To evaluate  the pharmacokinetics  of secukinumab  doses  in subjects  
Study design Multi- center,  open label,  parallel  group,  two arm study.  
Three  periods,  screening  (up to 4 weeks),  treatment  (of 208 weeks)  and follow -up 
(of 16 weeks)  
Population  Approximately  80 pediatric  subjects  aged  6 years  to less than 18 years  with 
moderate to severe chronic plaque psoriasis will be enrolled.  
Key Inclusion  criteria  Written informed assent and parental permission obtained at screening. Subjects 
reaching the age of consent during the study, will need to also sign the 
corresponding study Informed Consent.  
Must  be 6 to less than 18 years  of age at the time of randomization.  

Novartis  Confidential  Page  14 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
 Moderate  to Severe plaque  psoriasis,  defined  as a PASI  score  ≥ 12, and IGA mod 
2011 score of  ≥ 3, and Body Surface Area (BSA) involvement of ≥ 10%, at 
randomization 
History  of plaque  psoriasis  for at least 3 months  before  randomization  
Subject being regarded by the investigator to be a candidate for systemic therapy 
because of:  
inadequate  control of symptoms  with topical treatment,  and/or  
failure to respond to or tolerate previous systemic treatment and/or ultraviolet 
therapy  
Key Exclusion  criteria  Forms  of psoriasis  other  than chronic  plaque -type (eg pustular,  erythrodermic  and 
guttate psoriasis), active at randomization  
Female subjects of childbearing potential (menarchal or becoming menarchal 
during  the study)  who do not agree  to abstinence  or, if sexually  active,  do not agree 
to the use of contraception.  
Active ongoing inflammatory diseases other than psoriasis that might confound 
the evaluation of the benefit of secukinumab therapy  
Underlying  condition  (including,  but not limited  to metabolic,  hematologic,  renal, 
hepatic , pulmonary,  neurologic,  endocrine,  cardiac,  infectious  or gastrointestinal) 
which in the opinion of the investigator significantly immunocompromises the 
subject and/or places the subject at unacceptable risk for receiving an 
immunomodulatory therapy.  
History of an ongoing, chronic or recurrent infectious disease, or evidence of 
tuberculosis infection.  
History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years prior to screening.  
Activ e systemic infections during the last two weeks prior to randomization and 
any infections that reoccur on a regular basis.  
Study treatment  Secukinumab  prefilled  syringes  available  as 75 mg /0.5 mL and 150 mg/1  ml will 
be provided by Novartis in an open -label fashion.  
Efficacy  assessments  Investigator’s  Global Assessment (IGA  mod 2011) 
Psoriasis Area and Severity Index (PASI)  
Key safety  assessments  Adverse  Events 
Physical Exam 
Vital Signs  
Height and Weight 
Laboratory  evaluations  (hematology,  clinical  chemistry,  urinalysis) 
ECG  
Pregnancy  and assessments  of fertility  
Other  assessments Pharmacokinetics 
Immunogenicity  IG 

Novartis  Confidential  Page  15 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
 Children’s  Dermatology  Life Quality  Index  (CDLQI)  
Data  analysis  PASI 75 response at Week 12 and IGA 0 or 1 response at Week 12 will be 
evaluated and compared to historical placebo control. The secondary variable of 
PASI 90 response at Week 12 will be analyzed in the same way as the primary 
variable.  Efficacy  analysis  will report  the Bayesian  posterior  of the log-odds  ratio 
between  the secukinumab  treatment  groups  and the historical placebo  control.  The 
median, 95% CI and the probability of a positive treatment difference of the 
posterior  logs odds  ratio will be presente d. The co-primary  efficacy  variables  and 
secondary  efficacy  variables  will be analyzed  using the Full Analysis  Set (FAS). 
Key words  Pediatric,  psoriasis, children,  adolescents,  secukinumab  

Novartis  Confidential  Page  16 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Introduction  
1.1 Background  
Psoriasis  is a chronic relapsing inflammatory  skin disease with an estimated  prevalence of 0.32% 
in children under the age of 18 in 1996 (National Center for Health Statistics of the Centers for 
Disease Control and Prevention 1996). Since then, more epidemiologic studies have provided estimates on the prevalence of psoriasis in children  in Europe and the United States of America.  
• In the United  Kingdom, prevalence of psoriasis  was 0.55% in children  aged  0 to 9 years 
and 1.37% in children and adolescents aged 10 to 19 years, with a higher prevalence in girls than in boys ( Gelfand et al 2005).  
• In Germany, 0.71% of children  were  affected  by psoriasis  and the prevalence increased 
from 0.12% at the age of 1 year to 1.2% at the age of 18 years ( Augustin et al 2010 ). 
• Results from a survey among dermatologists  and general practitioners  in the Netherlands 
suggested a prevalence of 0.37% in children aged 0 to 10 years, and 1.09% in children aged 11 to 19 years ( de Jager et al 2009 ). 
• In the USA, a Southern California study in children enrolled in an integrated health plan reported a 0.30% prevalence of psoriasis in children aged 2 to 19 years. The prevalence increased consistently after 5 years of age and was higher in females than in males. Stratification by  gender (males vs. females) and age group yielded an overall prevalence 
of 0.17 % vs 0.21%; ages 2-5 years,  0.03% vs. 0.04%; ages 6-11 years, 0.16% vs. 0.15%; 
ages 12-19 years,  0.25% vs. 0.33% ( Wu et al 2011).  
The incidence of psoriasis in childhood in the US has been shown to increase with increasing age but also in recent  years  the incidence of psoriasis  in children  increased  significantly  from 
29.6 per 100,000 in 1970-1974 to 62.7 per 100,000 in 1995-1999 ( Tollefson  et al 2010).  
Plaque psoriasis affects 80% to 90% of all psoriasis subjects of all age -groups ( Griffiths and  
Barker 2007 , Pariser et al 2007 ) and hence is the most common variant in pediatric subjects. 
Most children manifest with plaque psoriasis in  patterns similar to adult subjects, with lesions 
localized  to the scalp,  post auricular  region, elbows, and knees;  however, lesions in children  are 
often smaller, thinner, and less scaly than those seen in adults. Involvement of the face and flexural regions is more  common in children  than adults, and psoriatic  lesions in the diaper area 
are prevalent during infancy. 
As in adults, pediatric psoriasis is frequently associated with significant co -morbid
 ities like 
diabetes mellitus, Crohn’s disease, obesity, and hypertension, and high cholester ol, 
psychological and psychiatric impact. The overall rate of comorbid conditions in psoriasis 
subjects under 20 years of age is double that of their peers  who do not have psoriasis  (Augustin  
2010). A pediatric study using an international cohort of psoriasis subjects found that a significantly higher percentage of children with psoriasis showed excess adiposity (37.9% vs. 20.5%) or obesity (20.2% vs. 7.3%), significantly higher than the general pediatric population 
(Paller et al 2013 ). 
The psychological impact  of psoriasis  can be particularly  traumatic  to children  and adolescents. 
In children with at least one of 12 different skin diseases, children with psoriasis reported the greatest impairment to quality of life. Itch or pain was reported in the same study as the most  

Novartis  Confidential  Page  17 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
significant problem affecting their Health -related Quality of Life (HrQoL) (Beattie 2006). 
Psoriasis, a debilitating and disfiguring skin condition, is an independent risk factor for 
psychiatric comorbidities  in children  and adolescents.  Compared with a matched  psoriasis- free 
control cohort in a study based  on health  services  claims data in the USA,  pediatric  subjects had 
approximately 25% to 30% greater  risks  of being given a diagnosis of any psychiatric disorder, 
depression, or anxiety subsequent to the psoriasis diagnosis ( Kimball et al 2012 ). 
Due to the higher prevalence of plaque psoriasis in children compared to other types and the significant physical and psychological burden it carries in the pediatric population, Novartis plans to study secukinumab in the treatment of plaque psoriasis in patients from 6 to less than 
18 years of age. 
The treatments for psoriasis have expanded over the past decade though in children treatment 
is frequently  off-label. The use of topical therapy in childhood is the first line of treatment for 
skin- limited disease. With chronicity of illness and in more severe cases, phototherapy and 
systemic the rapy are added to help induce remission ( Silverberg 2009).  
Topical therapies represent  the vast majority  of prescriptions (57 to 91%), while  systemic  agents 
are rarely used (4%), and biologics being even more rarely used (0.4%) (Wu 2011, Kimball 
2012). Commonly used topical treatments for psoriasis include corticosteroids, coal tar, anthralin, calcipotriol either alone or in combination with topical steroids, tazarotene and calcineurin  inhibitors  (Burden 1999, Farber  1999, Benoit 2007).  None of these treatments  have 
been  approved  for the treatment of psoriasis  in children below  12 years of  age.  Phototherapy is 
extensively used in adults and is a treatment option for some children with widespread  plaques. 
Narrow -Band -Ultraviolet B (UVB) is considered the first -line phototherapy because it is 
similarly  effective as Psoralen  + Ultraviolet A (PUVA),  more  convenient, and less carcinogenic 
(Van Weelden 1990). PUVA therapy is not generally recommended in children, but may be used with caution in adolescents ( Burden 1999).  
Systemic therapy  is usually  considered if the disease is moderate  to severe in intensity,  and not 
adequately controlled by topical therapies. Systemic treatments approved for use in adult psoriasis  include acitretin,  methotrexate,  cyclosporine, and biologics. Acitretin  is approved for 
subsets of psori atic pediatric  patients  in some European Union (EU)  countries and Switzerland. 
However cyclosporine and methotrexate are not currently approved for the treatment of children/adolescents suffering from psoriasis.  
Use of methotrexate, cyclosporine, retinoids  (parti
 cularly acitretin), and, with a much lower 
frequency, dapsone and hydroxyurea has been reported in the literature ( Zappel 2004; Benoit  
2007).  Most  experience has been  reported  with retinoids, but the potential effect  on bone growth 
and teratogenicity limit their use in children and adolesc ents. Use of cyclosporine and 
methotrexate is limited by their adverse event (AE) profile (kidney dysfunction, hypertension and liver dysfunction, respectively). Reports on the use of biologics in pediatric patients are scarce ( Benoit 2007).  
Amongst biologics, etanercept  and ustekinumab have been  approved not so long ago in  US for 
moderate to severe psoriasis in pediatric patients (ustekinumab only for adolescents that is children 12 years or older). In Europe, apart from etanercept and ustekinumab (ustekinumab only for adolescents),  adalimumab  has also been  approved recently  but only for severe psoriasis  

Novartis  Confidential  Page  18 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
in children  from 4  years  of age. The details are available  in respective prescribing  information  
/ summary  of product characteristics.  
In summary,  a very limited  number of systemic drugs for the treatment  of psoriasis  are approved 
for children, and the few approved drugs all have limitations. There is a high medical need to 
evaluate the treatment of psoriasis  in patients  less than 18 years  of age where  controlled  studies 
are mostly missing (Burden 1999; Farber 1999 ; Benoit 2007 ; Paller et al 2008 ). 
Secukinumab (AIN457) is a recombinant high -affinity fully human monoclonal anti -human 
Interleukin -17A (IL -17A) antibody of the Immunoglobulin IgG1/κ -class. Secukinumab binds 
to human IL -17A and neutralizes the bioactivity of this cytokine. IL -17A is the central 
lymphokine of a newly defined subset of inflammatory  T cells, the T helper 17 cells which, in 
several  animal  models, are pivotal in several  autoimmune and inflammatory  processes.  IL-17A 
is mainly produced by memory effector CD4+ and CD8+ T lymphocytes. IL -17A is being 
recognized as one of the principal pro- inflammatory cytokines in immune mediated 
inflammatory  diseases.  Its neutralization  is expected  to treat the underlying pathophysiology of 
immune mediated disease, and as a consequence provide relief of symptoms.  
Based  on the natural history  of psoriasis and the similar clinical  features and histology in adults 
and pediatric  population ( Burden 1999; Farber  1999; Benoit 2007),  it is expected  that a human 
monoclonal antibody such as secukinumab will have an identical mode of action in children when compared to adults. It is also expected that the exposure -response to secukinumab in 
pediatric psoriasis patients would be similar to the exposure -response relationship observed in 
adults.  
Now that efficacy  and safety  have  been  demonstrated in adults  in a comprehensive phase II/III 
program, it seems appropriate that the pediatric population can be exposed to secukinumab in long term studies with a dosing regimen that is extrapolated from the adult efficacious dose.  
Currently, another clinical trial (CAIN457A2310) with secukinumab is already ongoing in pediatric patients with severe psoriasis. This pl anned trial (CAIN457A2311) will assess 
efficacy,  safety  and pharmacokinetics of secukinumab  in moderate psoriasis (pediatric) patients 
as well as a few severe psoriasis patients.  
1.2 Purpose  
The purpose of this study is to assess the efficacy of secukinumab at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years at randomization with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy.  
This study will provide efficacy, safety and pharmacokinetic data to support the extension of label  of secukinumab to  include children  and adolescents (6 years to  <18 years)  with  moderate 
to severe chronic pl aque psoriasis.  
Moreover, this 
 study will assess the long- term efficacy,  safety  and tolerability  of secukinumab 
over a period  of up to 4 years to support the long- term use of secukinumab in pediatric  patients.  

Novartis  Confidential  Page  19 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Study  objectives and  endpoints  
2.1 Objectives  and related endpoints  
Table  2-1 Objectives and related endpoints  
 
Objective(s)  Endpoint(s)  
Primary  Objective(s)  Endpoint(s)  for primary  objective(s)  
To evaluate the efficacy of secukinumab in 
pediatric  subjects  aged 6 years  to less than 18 
years old with moderate to severe chronic plaque psoriasis with respect to PASI 75 and 
IGA mod 2011 0 or 1 response (co- primary 
endpoints) at Week 12, compared to pl acebo 
(historical control).  Proportion of subjects who achieved PASI 75 and 
IGA mod 2011 0 or 1 response at Week 12 in each secukinumab  treatment  group (low dose and 
high dose). Placebo data are obtained from adult 
secukinumab placebo- controlled trials and 
pediatric placebo- controlled trials with 
secukinumab or other biologics  
Secondary  Objective(s)  Endpoint(s)  for secondary  objective(s)  
To evaluate the efficacy of secukinumab in 
pediatric  subjects  with respect  to PASI  90 at 
Week 12, compared to placebo (historical control).  Proportion of subjects  who achieved PASI  90 
response at Week 12 in each secukinumab treatment group (low dose and high dose).  
Placebo data are obtained from adult placebo- controlled trials  and pediatric  placebo -controlled 
trials 
To investigate  the clinical  safety  and tolerability 
of secukinumab as assessed  by growth,  weight 
gain, vital signs, clinical laboratory variables, 
ECGs, and adverse event monitoring  Height  and weight,  vital signs,  laboratory 
evaluations, ECG and adverse events  
To evaluate the pharmacokinetics  of 
secukinumab in pediatric subjects  Secukinumab  concentration in serum  at various 
time points  
Exploratory  Objective(s)  Endpoint(s)  for exploratory  objective(s)  
To investigate the effects  of treatment  with 
secukinumab with respect to changes in 
CDLQI over time up to End of Treatment  Absolute and percentage change from baseline of 
CDLQI score over time up to End of Treatment  
To investigate  the effects  of treatment  with 
secukinumab  with respect  to CDLQI  0 or 1 
score over time, up to End of Treatment  Proportion  of subjects  achieving  CDLQI  0 or 1 
over time up to End of Treatment  

Novartis  Confidential  Page  20 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
Exploratory  Objective(s)  Endpoint(s)  for exploratory  objective(s)  
To investigate the development of 
immunogenicity  against  secukinumab  Development  of anti-Drug  Antibodies  (ADA)  to 
secukinumab  
 
Investigational  plan 
3.1 Study  design 
This is an open- label, parallel -group, two- arm, multi- center, trial in pediatric subjects aged 6 
years to less than 18 years,  at randomization, with moderate to severe chronic, plaque psoriasis. 
Approximately 80 subjects (at least 60 subjects with moderate severity) will be enrolled. It is 
expected  that subjects will be enrolled in about 40 centers  worldwide. It will be targeted  to have 
at least 5 subjects in the < 25kg weight,  and at least 10 subjects in each of the other two weight 
groups.  
Figure 3-1 Study design  
 
 
The study consists of 3 periods: screening  (up to 4 weeks),  treatment  (of 208 weeks) and  post- 
treatment follow -up (of 16 weeks). An outline of the visits is presented in Figure 3-1  while a 
detailed visit and assessment schedule can be found in Table 6 -1, Table 6 -2. 

Novartis  Confidential  Page  21 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Screening Period  
The screening period of up to 4 weeks will be used to assess eligibility of the subjects and to 
taper subjects off prohibited medication.  
Treatment Period  
The treatment period is de fined as randomization  to Week  208. In this period the endpoints  are 
assessed and subjects are followed for long -term safety and efficacy. Subjects will be 
randomized using 1:1 ratio into either secukinumab low dose or secukinumab high dose. Randomization will be stratified by body weight (< 25kg, 25- < 50 kg, ≥ 50kg) and disease 
severity (either moderate (PASI  score 12 -<20 and IGA 3 or 4 or PASI score ≥ 20 and IGA 3) 
or severe (PASI  score ≥ 20 and IGA of 4),  collected  at Randomization  Visit.  The study  aims  to 
recruit at least 60 subjects with moderate disease severity an d approximately 20 subjects with 
severe disease severity. It will be targeted to have at least 5 subjects in the < 25kg weight, and at least 10 subjects in each of the other two weight groups. Subjects will receive the appropriate 
dose based on their body weight category. If a subject moves into a higher or lower weight group at two consecutive visits  with weight measurements  during the maintenance (from Week 
12 onwards as assessed at 4 weekly  visits or during extension treatment period (as assessed at 
scheduled site visits), the subject will receive dosing according to the new (higher or lower) weight group respectively. The dose will be adapted starting from the visit of the second consecutive weight change.  
Adolescents  (12-
 < 18 years)  and children  (6-< 12 years)  can be included from  the beginning of 
this study, since the DMC has approved already the enrollment of children (6- < 12 years) in 
study CAIN457A2310. 
All subjects will visit the study site at Randomization (Day  1) and at Weeks 1, 2, 3, 4, 8, 12, 16 
during which they will receive either high -dose or low -dose secukinumab treatment sub - 
cutaneously. Additionally, subjects will visit the site at Weeks 13, 14, 15 to provide blood 
samples for pharmacokinetics. 
During the Treatment  period  subjects  will receive treatment  of the assigned  secukinumab  dose 
every  4 weeks. However during Weeks 16- 52 site visits will be scheduled every  8 weeks and 
from Weeks  64-208 site  visits  will be scheduled  every  12 or 16 weeks,  to minimize  the burden 
on the subject. Subjects will have the option to receive treatment between scheduled visits at 
home, following instructions provided to the subject (if ≥12 years old), parent or caregiver.  
Subjects who discontinue study treatment  for any reason  before  the end of the Treat ment  Period 
(Week 208) should have the Week 208 visit assessments performed approximately 4 weeks 
after their last dose of secukinumab. The subject will then enter the treatment– free Follow -up 
Period.  
Follow -up Period  
The treatment- free follow -up visits will be at Week 212, Week 216 and Week 224 (End Of 
Follow- up/EOF). Subjects who complete or discontinue the treatment early are expected to 
perform the complete treatment- free follow -up period unless they start another systemic anti - 
psoriatic  treatment.  In this case they do not need  to continue with the remaining  follow-up 

Novartis  Confidential  Page  22 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
visits but will be expected to return to the site after the start of the systemic treatment and 
perform the EOF visit.  
3.2 Rationale  for study  design  
The rationale behind this design is based on a full extrapolation approach. Novartis’ proposal for a pediatric extrapolation approach is based on the Food and Drug Administration draft guidance, General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biologic al Products, which  is also reflected  in ICH E11 (R1) guidance and an European Medical 
Association reflection Paper on extrapolation of efficacy and safety in pediatric medicine development ( ICH 2000; FDA 2014; EMA 2016; ICH 2016).  
Its intent  is to minimize  exposure of children  to placebo  and to overall clinical  trial burden while 
leveraging the broad clinical  information  available from secukinumab trials  in adult subjects as 
well as ongoing pediatric  trial CAIN457A2310. This approach is considered appropriate due to 
the substantial similarity of the disease between the adults and pediatric population ( Augustin 
2010, Feldman and Krueger 2005, Griffiths 2007 , Kimball 2012, Langley et al 2005, Leman  
and Burden 2001, Paller et al 2008 , Pariser 2007 , Tollefson 2014) as well the similarity of 
exposure-response, which  will be validated in  the small  population of children  and adolescents 
of this study. The similarity  of disease characteristics of psoriasis between adult and pediatric 
subjects has been described extensively.  
Following consultation with Health Authorities (FDA and EMA (PDCO) for overall pediatric program, the open label, design with no control arm was chosen for this particular study. Collection of pharmacokinetic information for pediatric subjects based on age  and/or weight 
strata was recommended. In principle, if pediatric doses matching adult exposures are reasonably  identified,  then an uncontrolled open- label  trial in pediatric  subjects to collect  safety 
and efficacy data can be acceptable. An interim PK analysis of data from the ongoing CAIN457A2310 trial (a double -blind placebo controlled and single blind active -controlled 
study in pediatric subjects with severe psoriasis) showed that pediatric trough concentrations for the weight  and dose groups studied are consistent with the predictions from a population PK 
model in psoriasis patients (data on file; see Section 3.3 for more details ). 
The present study is  being  conducted to collect  long term  safety  data  and evaluate efficacy  and 
pharmacokinetics in children. The efficacy data collected in this uncontrolled study will be compared with historical  placebo  data obtained from  the adult program with secukinumab  and 
pediatric  placebo -controlled  trials  with other biologics.  If data from CAIN457A2310 (pediatric 
subjects with severe psoriasis) are available when this study report is created, the placebo efficacy data may also be used in the efficacy analysis of study CAIN457A2311. 
Finally,  the low
 er age of enrollment has been  limited  to 6 years since the prevalence of psoriasis 
in the 0 to less than 6 age group is very low (with the highest prevalence published of 0.3%) 
and the proportion of children with a severe condition in need of a systemic treatment is 4%, giving a final prevalence of the condition to be about 1 per 10,000 in this age group. 

Novartis  Confidential  Page  23 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
3.3 Rationale  for dose/regimen,  route of administration  and duration 
of treatment  
The dose selection for secukinumab in pediatric psoriasis subjects is based on the completed 
phase III program in adults as well as on modeling and simulation based on the results from adult phase II/III studies. Secukinumab 300 mg and 150 mg are selected based on evidence from adult phase III studies that demonstrated both doses to be safe and effective in treating moderate to severe plaque psoriasis.  
The same doses were also selected for the first and ongoing pediatric study CAIN457A2310 which  is a double- blind  placebo  controlled  and single blind active -controlled study in pediatric 
subjects with severe psoriasis.  
The proposed doses for the high dose and low dose secukinumab arms are based on a population- PK model that has been built based on the pool of key phase II/III adult trials to 
predict exposure of secukinumab according to various body weights. This dosing rationale assumes that the concentration- response relationship  and disease characteristics  (onset, severity, 
progression) in children are similar to adults with no major differences in target expression of 
IL-17A. Therefore,  similar  PK concentration profiles  across the  adult and pediatric  populations 
will achieve comparable response.  
Figure 3-2 Average concentration for the proposed low dose and high dose 
secukinumab arms 
 
Extrapolation  of the exposure in children  / adolescents  in a bodyweight range down to 20 kg to 
allow maintaining exposure levels similar to those observed in adults with 50 kg body weight led to selection of 75mg, 150 mg and 300 mg within weight categories as follows:  
• Subjects ≥50 kg: 150 mg (low dose group) or 300 mg (high dose group)  
• Subjects 25 kg to < 50 kg: 75 mg (low dose group) or 150 mg (high dose group)  
• Subjects < 25 kg: 75 mg (for both dose groups in order to ensure no overly high exposures 
in this sub-population). 

Novartis  Confidential  Page  24 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Interim PK data from 23 secukinumab -treated subjects in the age range of 12 to 17 years old 
from study  CAIN457A2310 have been evaluated (data on file). The observed pediatric trough 
concentrations are consistent with model predictions for the weight and dose groups studied. 
These data, therefore, support the selected dosing regimen from a safety and efficacy point of view for study CAIN457A2310 and for the present study CAINA457A2311. 
3.4 Rational  for choice  of comparator 
No comparator drug is included in this study. Historical placebo  data from qualifying trials  will 
be used as the control for primary  and key secondary  endpoint analysis as discussed  in Section  
9.4. This is in line with guidance from  and discussions with Health  Authorities  including  FDA 
and EMA (PDCO) which suggested reducing placebo exposure as well as overall clinical trial burden for pediatric population and suggest/accept use of extrapolation approach. 
3.5 Purpose  and timing  of interim  analyses/design  adaptations  
There are two planned  interim analysis. An interim analysis, including the primary endpoint 
(Week 12) analysis will be conducted when all subjects have completed the Week 16 visit or the premature  treatment discontinuation visit.  Another interim  analysis  will be performed  when  
all subjects have completed  the Week  52 visit or the  premature treatment discontinuation visit.  
Additional analyses  may be performed to support health authority interactions, as necessary.  
Thereafter, efficacy and safety data collected after Week 52 until  the end of study may be 
reported yearly in separate reports.  
Trial modifications  are not planned based  on any interim  analysis.  
3.6 Risks  and benefits  
The risk to subjects in this trial will be minimized by compliance with the eligibility criteria 
and study procedures and by close clinical monitoring. 
Biologics are  being considered a safe and effective  option for treating  psoriasis  in the pediatric 
popul ation  as they are convenient to use, requiring less frequent dosing than traditional systemic 
agents such as methotrexate, cyclosporine, and acitretin. In addition, they lack many of the 
potential end- organ toxicities of traditional agents because of their  targeted action.  
Results from non -clinical studies and phase II and  III clinical studies in adults did not reveal a 
safety concern that would preclude the use of secukinumab in children. In adult studies, secukinumab has shown a very good efficacy profile in the treatment of moderate to severe chronic plaque psoriasis. The  safety data from the completed and ongoing studies, including 
Adverse Event and Serious Adverse Event data, laboratory parameters and immunogenicity data, demonstrate a good safety profile. 
Known risks of secukinumab administration includes an increased risk of infections, in 
particular candida infections, neutropenia and hypersensitivity reactions that can be seen with administration of any foreign proteins. Most of the infections were non- serious upper 
respiratory  tract infections  and candidiasis,  mild to moderate  in severity,  clinically  manageable 
and did not lead to treatment discontinuation. Cases of neutropenia were  uncommon, generally  

Novartis  Confidential  Page  25 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
mild to moderate and transient and did not lead to treatment discontinuation, and only a few 
cases were timely associated with non -serious infections.  
Potential risks for subjects on secukinumab may include malignancies, major adverse cardiovascular events (MACE), Crohn’s disease, immunogenicity, and interactions with live 
vaccines.  
Since the immune system was shown to reach adult levels of maturation by 6 years of age (Comans- Bitter et al 1997 ), no adverse effects of secukinumab on development of this system 
are expected in this trial’s pediatric population (age 6 to < 18 years). Consequently, no additional risks of infections, malignancies, or impact on peripheral competent immune cells over those described for adults are anticipated for this pediatric group.  
A potential for increased exposure of secukinumab at lower body weights has been suggested by the analysis of population pharmacokinetic data. Consequently, weight category based dosing has been  instituted  to ensure that exposure levels of secukinumab are comparable across 
all weight groups in the study population. 
No adverse effects are anticipated with respect to linear bone growth and development given 
the absence of bone findings in knock -out mice ( Kokubu et al 2008) and in toxicology studies 
with secukinumab. Height, to measure linear growth, will be monitored throughout the study. 
Prior to participating in a clinical tria l with secukinumab, participants should consider 
completion of all age appropriate immunizations according to immunization guidelines. 
Subjects treated with secukinumab should not receive live vaccines. Non- live vaccinations 
received  during secukinumab  treatment  may not elicit an immune  response sufficient  to prevent 
disease (refer to Table 5 -3). 
 
Population 
The study population will consist of male  and female  subjects age 6 to less than 18 years  of age 
(at the start of study treatment) with moderate  to severe plaque  psoriasis who are candidates for 
systemic treatment.  
The investigator must ensure that all subjects being considered for the study  meet  the following 
eligibility  criteria.  No additional exclusions should be applied by the investigator,  in order that 
the study population will be representative of all eligible subjects.  
Approximately 80 subjects (at least 60 with moderate psoriasis) will be rand omized in 
approximately 40 centers worldwide. Since a 15% screening failure rate is expected, approximately 95 subjects will be screened. 
4.1 Inclusion  criteria  
Subjects eligible  for inclusion in this study must fulfill all of the following criteria: 
1. Written informed assent and parental permission (age as per local law) obtained at 
screening  before any assessment  is performed. Of note, if subjects reach  age of consent 
(age as per local law) during the study, at that time they will need to also sign the  
corresponding study Informed Consent. 
2. Must  be 6 to less than 18 years of age at the time of randomization.  

Novartis  Confidential  Page  26 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
3. Moderate to Severe plaque psoriasis,  defined as a PASI  score ≥ 12, and IGA mod 2011 
score of  ≥ 3, and BSA involvement of ≥ 10%, at randomization 
4. History  of plaque psoriasis for at least 3 months before  randomization  
5. Subject being  regarded  by the investigator to be a candidate for systemic therapy because 
of: 
• inadequate control of symptoms  with topical treatment,  and/or  
• failure  to respond to or tolerate  previous systemic treatment and/or UV therapy  
4.2 Exclusion  criteria  
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible subjects/subjects.  
1. Forms  of psoriasis  other  than chronic plaque- type (eg, pustular, erythrodermic  and guttate 
psoriasis), active at randomization.  
2. Drug -induced psoriasis  (ie new onset or current exacerbation  from  beta-blockers,  calcium 
channel blockers or lithium)  
3. Ongoing use of prohibited treatments  as mentioned in Table  5-3 (Washout periods as 
detailed in Table 5 -3 have to be adhered to). 
4. Previous exposure to secukinumab or any other biologic drug directly  targeting  IL-17 or 
the IL -17 receptor,  
5. Use of any other investigational treatment within  30 days for small  molecules or within  a 
period of 5 half- lives of the investigational treatment from randomization, or until the 
expected pharmacodynamic effect has returned to baseline, whichever is longer. 
6. History  of severe hypersensitivity reaction  or anaphylaxis to any biological agent (human 
monoclonal antibody or soluble receptor)  
7. Pregnant or nursing (lactating) females, where pregnancy is defined as the state of a female  after conception and until the termination  of gestation, confirmed  by a positive 
human Chorionic Gonadotropin (hCG)laboratory test 
8. Female subjects of childbearing potential and/or who are at least 12 years of age; defined as
 all women physiologically capable of becoming pregnant, unless they are using 
effective methods of contraception during dosing and for 16 weeks after stopping study treatment (or longer if local  label  requires  it (eg in EU 20 weeks),  (menarchal  or becoming 
menarchal during the study) who do not agree to abstinence or, if sexually active, do not agree to the use of contraception. Effective contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject).  Periodic abstinence (eg, calendar,  ovulation, symptothermal,  post-ovulation 
methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or tubal ligation  at least six weeks before taking 
investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow- up hormone level assessment  
• Male sterilization  (at least 6 months prior to screening). For female  subjects on the 
study, the vasectomized male partner should be the sole partner for that subject  

Novartis  Confidential  Page  27 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault  caps).  For United  Kingdom: with spermicidal foam/gel/film/cream/ 
vaginal suppository  
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms  of hormonal contraception that have comparable efficacy  (failure 
rate < 1%), for example hormone vaginal ring or transdermal hormone contraception 
In case of use of oral contraception  women  should have been  stable on the same pill for 
a minimum of 3 months before taking investigational drug. 
In case local  regulations  deviate from  the contraception  methods listed  above, local 
regulations apply and will be described in the Informed Consent Form 
9. Active  ongoing inflammatory  diseases other than psoriasis  that might confound the 
evaluation of the benefit of secukinumab therapy 
10. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, 
pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly  immunocompromises the subject and/or places  the 
subject at unacceptable risk for receiving an immunomodulatory therapy. In addition, current  severe progressive or uncontrolled diseases which  render the subject unsuitable for 
the trial or puts the subject at increased risk, including  any medical or psychiatric 
condition which, in the Investigator’s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol. 
11. Investigator discretion  should be used for subjects with preexisting  or recent -onset central 
or peripheral nervous system demyelinating disorders 
12. Subjects with an estimated  Glomerular Filtration  Rate (eGFR),  estimated  by the Schwartz 
equation, of < 60 mL/min/1.73 m
2 at screening.  Assessment  may be repeated  once, two or 
more days later, and if eGFR value ≥  60, subject may be included at the discretion of the 
investigator.  
13. Subjects with total White  Blood Cell count < 2,500/μL, or platelets < 100,000/μL  or 
neutrophils < 1,500/μL or hemoglobin < 8.5 g/dL at screening 
14. Active systemic infections during the last two weeks (exception: common cold) prior to randomization and any infections that reoccur on a regular basis. Investigator/qualified site staff discretion should be used regarding subjects who have traveled or resided in areas of endemic mycoses, such as histoplasmosis, coccidioidomycosis or blastomycosis and for subjects with underlying conditions that may predispose them to infection, such as 
advanced or poorly controlled diabetes 
15. History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection  as defined by a positive central  laboratory  test result  at screening.  Subjects with a 
positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatm ent must have 
been initiated and maintained according to local country guidelines prior to  
randomization.  

Novartis  Confidential  Page  28 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
16. Past medical  history  record  of, or known current infection  with Human  Immunodeficiency 
Virus, hepatitis B or hepatitis C at screening  
17. History  of lymphoproliferative  disease or any known malignancy or history  of malignancy 
of any organ system within the past 5 years prior to screening, except for skin Bowen’s 
disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non- 
invasive malignant colon polyps that have been removed. 
18. Plans  for administration  of live vaccines during the study period or within  6 weeks prior to 
randomization.  
19. Any medical  or psychiatric  condition which, in the Investigator’s  opinion, would preclude 
the participant from adhering to the protocol or completing the study per protocol.  
20. Hypersensitivity or allergy  to any of the ingredients  of study treatment 
21. History  or evidence of ongoing alcohol or drug abuse,  within  the last 24 weeks before 
randomization.  
22. Subjects not willing  to limit UV light exposure (eg, sunbathing and/or the use of tanning 
devices) during the course of the study. 
23. Unwillingness to undergo repeated  venipuncture or subcutaneous injections.  
 
Treatment  
5.1 Study  treatment  
5.1.1 Investigational  and control  drugs  
Secukinumab prefilled syringes available as 75mg/0.5ml and 150mg/1ml will be provided by Novartis in an open- label fashion.  
Syringes will be labeled  as: 
• AIN457  75mg/0.5 mL or 
• AIN457  150mg/1mL  
5.1.2 Additional  treatment  
No additional treatment  beyond investigational drug is included in this trial. 
5.2 Treatment  arms  
Subjects will be randomized using a 1:1 ratio at the Randomization visit to two treatment 
arms, secukinumab low dose or secukinumab high dose. Subjects will receive sc dose according to the weight category  (< 25 kg, 25- < 50kg, ≥ 50 kg). 
Subjects in  the two secu
 kinumab  arms  weighing ≥ 50kg will receive 150 mg (low dose group) 
and 300 mg (high dose group), 25 to < 50 kg will receive 75mg (low dose group) and 150 mg (high dose group) and < 25kg will receive 75mg for both dose groups as summarized in the Table  5-1 below. Subjects will be receiving  one sc injection  at each drug administration  of either 
secukinumab 75 mg or 150 mg Pre-filled  Syringe (PFS)  according to their treatment group.  

Novartis  Confidential  Page  29 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Only  the subjects in  the ≥  50 kg high dose treatment  groups will be receiving  two sc injections 
of 150 mg secukinumab at each administration. 
Secukinumab low dose group:  
According to the weight category, sc secukinumab 75 mg (in < 25 kg and 25 to < 50 kg) or 150 
mg (≥ 50 kg) injections will be administered  at Randomization, Weeks 1, 2, 3, 4 and thereafter 
every  4 weeks during the entire treatment period of the study until Week 204. After Week 16, 
treatment which occurs outside of the site visits, may  be administered at home every 4 weeks, 
either by subject (sel f-injection is allowed for subjects ≥ 12 years ) or parent/caregiver. If 
subject/parent does not feel confident in performing treatment administration at home they  are 
still allowed to receive study treatment administration at site.  
Secukinumab high dose group:  
According to the weight category, sc secukinumab 75 mg (in < 25 kg), 150 mg (in 25 to < 50 
kg) or 2 x 150 mg (≥ 50 kg) injections will be administered at Randomization, Weeks 1, 2, 3, 
4 and thereafter  every  4 weeks during the entire  treatment period  of the study until Week  204. 
After Week  16, treatment which  occurs outside of the site visits,  may be administered  at home 
every 4 weeks, either by subject (self -injection  is allowed for subjects ≥ 12 years ) or 
parent/caregiver. If subject/parent does not feel confident in performing treatment administration at home they are still allowed to receive study treatment administration at site.  
Table 5-1 Number  of injections per visit per treatment arm 
 
Weight  Dose  (PFS)  Number  of injections  at each  dosing  
<25 kg - low dose 75 mg 1 
-high dose 75mg  1 
25 to <50 kg - low dose  75 mg 1 
-high dose 150 mg 1 
≥50 kg - low dose 150 mg 1 
-high dose 300mg  2 
5.3 Treatment  assignment  and randomization  
At Randomization (Day 1) all eligible subjects/subjects will be randomized via Interactive 
Response Technology (IRT) to one of the two treatment arms. The investigator or his/her 
delegate will contact  the IRT after confirming  that the subject  fulfills  all the inclusion/exclusion 
criteria. The subject number, the weight of the subject, the age and any relevant information related to severity, as described in the user manual, will be entered. The IRT will assign a randomization number to the subject, which will be used to link the subject to a treatment arm and will specify  a unique medication  number for the first package of study  drug to be dispensed 
to the subject.  
The randomization numbers will be generated using the  following procedure to ensure that 
treatment assignment is unbiased. A subject randomization list will be produced by the IRT provider using a validated  system  that automates  the random assignment  of subject  numbers to 
randomization numbers. These randomization  numbers are linked to the different treatment  

Novartis  Confidential  Page  30 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
arms, which in turn are linked to medication numbers. A separate medication list will be 
produced by or under the responsibility  of Novartis Drug  Supply Management  using a validated 
system that automates the random assignment of medication numbers to packs  containing the 
investigational drug(s). 
Stratification  
Randomization will be stratified by disease severity and body weight collected at 
Randomization Visit. This stratification ensures balanced allocation of subjects to treatment groups within the diseas e severity and weight strata.  
The weight strata will be “body weight < 25 kg”, “25 kg ≤ body weight < 50 kg” or “body weight ≥ 50 kg” and disease severity  strata  (refer  to Table  5-2).  Stratification  by disease severity 
and body weight will occur at Randomization Visit. 
Table 5-2 Disease severity classification  
 
IGA PASI  score  Psoriasis  severity  
3 12-< 20 Moderate  
3 ≥ 20 Moderate  
4 12-< 20 Moderate  
4 ≥ 20 Severe  
It will be targeted to have at least about 5 subjects in the < 25kg weight, and at least about 10 subjects in each of the other two weight groups. 
The randomization scheme for subjects will be reviewed and approved by a member of the 
Integrated Quantitativ e Sciences Randomization Group. 
5.4 Treatment  blinding 
Medication will be labeled in an open- label fashion. Blinding requirements are not applicable 
for any of the parties involved. 
5.5 Treating the subject  
Sponsor qualified  medical  personnel will be readily  avail able to advise on trial related  medical 
questions or problems.  
5.5.1 Subject numbering  
Each subject is uniquely identified by a Subject Number assigned by Novartis. The subject number is composed of a site number and a sequential subject number. Once assigned to a subject, the Subject Number will not be reused. 
Upon signing the informed cons ent form, the subject is assigned the next sequential number 
available in the electronic data capture (EDC) system. The investigator or his/her staff will 
contact the IRT and provide the requested identifying information for the subject to register them into  the IRT.  The site must  select  the eCRF  book with  a matching  Subject Number  in the 
EDC system to enter data.  

Novartis  Confidential  Page  31 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
If the subject fails to be treated for any  reason, the IRT must be notified within 2 days that the 
subject was not treated. The reason for not being treated will be entered on the appropriate 
Screening period eCRF. 
5.5.2 Dispensing the study drug  
Each  study site will be supplied by Novartis with study treatment.  
At all visits  where  secukinumab  is dispensed, the IRT system  will allocate  a unique medication 
number which will be transmitted to the pharmacist (or other qualified site personnel) responsible for dispensation of study treatments. The pharmacist (or other qualified site personnel) will then identify the study treatment package(s) to administer to the subject corresponding to the medication number(s). The study drug packaging has a 2- part label. The 
unique medication  number  is printed on each part of this label.  Immediately  before preparation 
of the study treatment, the pharmacist (or other qualified site personnel) will detach the outer part of the label  from  the packaging and affix  it to the source document for that subject’s unique 
subject number. These documents will be kept in a secured location as appropriate. The study treatment will be administered by study nurse/ qualified site personnel individual.  
During the COVID-19 pandemic or similar major  health  care disruption  that limits  or prevents 
on-site study visits,  delivery  of study drug directly  to a participant’s  home is generally  permitted 
in the event the Investigator has decided that an on- site visit by the participant is no longer 
appropriate or possible, and that it is in the interest of the participant’s  health  to administer the 
study treatment even without performing an on- site visit. The dispatch of study drug from the 
site to the participant’s home remains under the accountability of the Investigator.  
At the site  level,  the agreement  with  approval of  the Principal Investigator,  Independent Ethics 
Committee/ Institutional Rev iew Board (IEC/IRB) and any other Board as appropriate should 
be in place to implement home delivery. 
Home  administration of secukinumab  
After Week 16, subjects/custodians will be expected to perform home administrations of 
secukinumab at the time  points s pecified  in the protocol,  when  they are not visiting  the site for 
other trial related procedures. Subjects/custodians must be previously trained by site staff regarding the administration of secukinumab PFS.  
It must be noted  that subjects 12- < 18 years of age can self-inject  only under caregiver  or health 
care professional supervision. Subjects < 12 years of age are not allowed to self –inject at any time.  
If the subject or custodian is not confident to administer medication at home, subjects should visit the site every 4 weeks and according to the visit schedule to have the administrations performed  there  by the  site staff.  Alternatively,  if possible, local  arrangements  can be done for 
a trained  nurse to administer  medication  to the subject  at home. This person must be sufficiently 
trained.  
For home administrations the pharmacist/ qualified site personnel will dispense, via IRT, an app
ropriate number of investigational treatment packages and detach outer part of the label 
from the packaging as indicated  above. The custodians/subjects will record the date(s)  of 

Novartis  Confidential  Page  32 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
administration  at home and will return  the used PFS and packaging at their next visit to the site. 
Site staff are to transcribe this information  into the appropriate Dosage Administration  Record 
eCRF.  
The used PFS should be disposed immediately  after use in a sharps container OR according to 
the requirements of the respective countries and brought back  to site. Subjects will be asked  to 
return all unused PFS the latest at the completion of the study  or at the time o f discontinuation 
of the investigational treatment. Detailed instructions will be provided separately.  
5.5.3 Handling of study and additional treatment  
5.5.3.1 Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely  and properly, and kept in a secured  location  to which  only the investigator and designees 
have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels. Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective Novartis Country Pharma Organization Quality Assurance.  
Medication lab els for secukinumab prefilled syringes will be in the local language and comply 
with the legal requirements of each country. They will include storage conditions for the investigational treatment but no information  about the subject except  for the medication number. 
They must be stored in a secured refrigerator at 2°C -8°C (36°F -46°F), and must be carefully 
controlled in accordance with regulations governing investigational medicinal products and local regulations. Study treatments should not be frozen and m ust be protected from light.  
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability  log. Monitoring  of drug accountability will be performed  by 
monitors  during site visits  or remotely  and at the completion  of the trial. Subjects will be asked 
to return  all used PFS and packaging at frequent intervals  (i.e. at next scheduled study visit) and 
unused PFS and packaging latest at the end of the study or at the time of discontinuation of study treatment. 
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return all unused PFS, packaging, drug labels, and a copy of the completed drug 
accountability  log to the Novartis  monitor or to the Novartis  address provided in the investigator 
folder at each site.  
5.5.3.2 Handling of additional treatment  
Not applicable.  
5.5.4 Instructions for prescribing and taking study treatment  
All study treatments will be administered subcutaneously throughout the study. All doses of study treatments at scheduled site visits will be administered at the study site after the study assessments for the visit have been completed. Prior to administration to the subject, the study treatment will be dispensed by the qualified site personnel appointed at the study site.  
For home administrations  the processes described  earlier  at Section  5.5.2 must be followed.  

Novartis  Confidential  Page  33 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
The first study  treatment  administration  will occur  at the Randomization Visit (Day  1), after all 
study scheduled  assessments  have been  performed  (and inclusion/exclusion criteria  confirmed) 
and only after the scheduled blood samples have been drawn. Similarly, at each other visit, all 
study assessments should be completed prior to the administration of study treatment. 
Subjects will  be administered  study medication  weekly  for the first 4 weeks  of the treatment 
period and then every 4 weeks until Week 204. During the Follow-up period, no study  medication  will be administered.  
Administration of secukinumab 
Secukinumab Solution for Subcutaneous Injection will be provided in Prefilled syringes (75 
mg/0.5 mL and 150 mg/1mL). 
The study treatment  solution  must  be injected  into non- affected areas of the skin.  
If possible, throughout the trial, the study treatment should be administered to body regions, 
changing the injection  site from visit to visit,  for example:  right thigh, left thigh, right abdominal 
area, left abdominal area.  
Single prefilled  s
 yringes will be packed  in individual boxes. The boxes containing  the syringes 
with study treatment  solution  should be kept at 2 to 8°C (36°F to 46°F) and protected  from  light. 
They  should not be frozen  or shaken. Prior to administration  the boxes containing  the syringes 
with study treatment solution should be  allowed to come to room temperature unopened for 
about 15-30 minutes before administration.  Used  syringes should be disposed immediately  after 
use in a sharps container or according  to the requirements of the respective countries. For home 
administration please refer to Section 5.5.2. Note 
: The removable cap of the secukinumab  pre-filled  syringe 1 mL and 0.5mL form contains 
a derivative of natural rubber latex.  Although no natural rubber latex  is detected  in the cap,  the 
safe use of the secukinumab  1 mL or 0.5 mL pre-filled  syringe in latex -sensitive  individuals has 
not been studied. All kits of study treatment assigned  by the IRT will be  recorded/databased in  the IRT. 
The investigator must promote compliance  by instructing  the subject to take the study treatment 
exactly as prescribed and by stating that compliance is necessary for the subject’s safety and 
the validity  of the study. The subject must also be instructed  to contact  the investigator if he/she 
is unable for any reason to take the study treatme nt as prescribed.  
5.5.5 Permitted  dose adjustments and interruptions of study treatment  
Investigational or other treatment  dose adjustments and/or interruptions  are not permitted.  
5.5.6 Rescue medication  
Rescue medication for psoriasis is not permitted in this study 
5.5.7 Prior and Concomitant medication  
Relevant  treatments  (excluding those for psoriasis)  taken  within  6 months from screening  date 
must be entered  in the Prior  and Concomitant Medications eCRF.  Any psoriasis treatments  used 

Novartis  Confidential  Page  34 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
from the time subject started to treat psoriasis will be reported on the Prior psoriasis therapy 
eCRF and not in the prior and concomitant medications eCRF. 
The investigator must instruct the subject to notify the study site about any new medications 
he/sh e takes after the subject was enrolled into the study. All medications, procedures and 
significant  non-drug therapies (including  physical therapy and blood transfusions) administered 
after the subject was enrolled into the study must be recorded in the app ropriate CRF.  
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt the investigator should contact the Novartis medical monitor before randomizing a subject or allowing a new medication to be started. 
5.5.7.1 Perm itted  concomitant  medications (not for psoriasis)  
Concomitant medications are allowed if not listed in Table 5 -3. Dose adjustments of these 
medications  should be avoided during the study. If a dose adjustment of these  medications does 
occur, they must be recorded on the Concomitant medications eCRF or the Procedures and 
Significant non- drug therapies eCRF.  
Subjects who are receiving treatments  known to worsen  psoriasis  (eg beta-blockers) must  be on 
stable dose for at least 4 weeks before Randomization Visit.  
Topical corticosteroids (TCS)  and other topical  treatments  will be allowed  from Week  12 visit 
and until the end of study  only if: medication  was started  after the week  12 visit was completed 
AND medication  was used for 14 consecutive calendar  days or less AND medication  was used 
for an indication other than psoriasis and not on the area affected with psoriasis.  
Use of these  TCS must be recorded  on the Concomitant medications TCS eCRF.  
There is no restriction on the use of anti -histamines or of corticosteroid drops used in the eye 
or ear during the study 
5.5.7.2 Permitted  concomitant medication for psoriasis  
After the screening period, the use of concomitant medication for psoriasis in all body regions 
is restricted to bland emollients (not supplied by Novartis) and other non -medicated 
interventions (not listed in Table 5 -3). Use of bland emollients must be reco rded on the 
Concomitant medications eCRF. Use of any other non -medicated interventions must be 
recorded on the Procedures and Significant non-drug therapies eCRF. 
The definition of “bland” excludes all topical medications that contain pharmacologically active 
ingredients  such as (but not limited  to) lactic  acid,  salicylic acid,  urea,  α-hydroxy acids or fruit 
acids.  
The use of bland  emollients  should be avoided during the 12 hours preceding a scheduled  study 
visit.  
A TCS treatment  
 of mild or moderate  activity  is allowed  for the face,  scalp,  and genitoanal area 
during the screening  period, but not after the subject  has been  randomized. These TCS must not 
be used during the 12 hours preceding the Randomization study visit. Use of these TCS must 
be recorded  on the Prior psoriasis  therapy  eCRF  if they were  used to treat psoriasis.  If not used 
to treat psoriasis they should be entered in the TCS eCRF ( Section 5.5.7.1 ). 

Novartis  Confidential  Page  35 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
5.5.8 Prohibited medication 
Use of any treatments displayed in Table  5-3 that could confound the efficacy  are NOT  allowed 
during the study for any indication and wash- out periods for these treatments prior to 
randomization are indicated in the table. If the use of these treatments is required, then the 
subject should NOT be randomized into the study 
The investigator should instruct the subject to notify the study site about any new treatments 
he/she takes after the start of the study treatment. All prohibited medications and significant 
non-drug therapies administered  after the subject  starts  treatment with  study treatment must be 
listed on appropriate eCRF. 
If a prohibited treatment listed in Table 5 -3 was used during the study, the subject must 
discontinue use of the prohibited treatment if he/she wishes to continue in the study. At the 
discretion of the investigator, if the subject’s use during the study of a prohibi ted treatment 
listed  in Table  5-3 presents  undue safety  risk for the subject, the subject  should be discontinued 
from study  treatment as per Section  5.6.2. If  the subject received  a live vaccination  during the 
study, the subject must discontinue study treatment. 
During the screening  period, subjects  will be allowed  to use some  active  topical treatments  for 
any indication in the following body regions: face,  scalp,  and genitoanal area.  The active  topical 
treatments are limited to: mild or moderate potency corticosteroid. The subject must stop use 
of these topical corticosteroids (TCS) at least 12 hours preceding the Randomization visit.  
For all other body regions, a washout period of 2 weeks applie s for all active  topical treatments 
for any indication as indicated in Table 5 -3 below 
The Sponsor will be notified if a prohibited treatment is taken while the subject is on study.  
Table 5-3 Prohibited medication  
 
Prohibited  Treatment  Wash -out period  up 
to Randomization  Treatment 
Period1,2 
Secukinumab No prior use allowed Used as study 
treatment  
Any biologic  drug directly  targeting IL-17 or the IL-17 receptor 
(other than secukinumab [eg brodalumab, ixekizumab])  No prior use allowed Not 
allowed  
Any biologic directly targeting IL -12/23 or IL -23, eg 
briakinumab,  stekinumab,  guselkumab,  tildrakizumab  26 weeks  Not 
allowed  
Alefacept,  efalizumab  26 weeks  Not 
allowed  
Etanercept  4 weeks  Not 
allowed  
Biological  immunomodulating agents  other  than above (eg, 
adalimumab, infliximab)  12 weeks  Not 
allowed  
Other systemic immunomodulating treatments (eg, methotrexate (MTX),  cyclosporine A [CSA], 
corticosteroid, cyclophosphamide)  4 weeks  Not allowed 
Photochemotherapy  (eg, PUVA)  4 weeks  Not 
allowed  

Novartis  Confidential  Page  36 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
Prohibited  Treatment  Wash -out period  up 
to Randomization  Treatment 
Period1,2 
Other  systemic therapy  for psoriasis  (eg, retinoids,  fumarates, 
apremilast)  4 weeks  Not 
allowed  
Any other  investigational  treatment  or participation  in any 
interventional trial  4 weeks  or 5 half- 
lives (whichever  is 
longer)  Not 
allowed 
Phototherapy  (eg, UVA,  UVB)  2 weeks  Not 
allowed  
Topical treatment3 for psoriasis or any other skin condition 
(eg, corticosteroids, vitamin D analogues, pimecrolimus, 
retinoids,  salicylvaseline,  salicylic  acid,  lactic  acid,  tacrolimus, 
tar, urea, α -hydroxy or fruit acids), except on the face, scalp, 
hand s and feet and genitoanal area during screening  2 weeks4 Not 
allowed 5 
Live vaccinations  6 weeks  Not 
allowed  6 
1 If a prohibited treatment of psoriasis is used during the study, the subject must discontinue use of the prohibited treatment if 
he/she wishes to continue in the study. 
2 In case  of undue safety risk for the subject, the subject should discontinue study treatment at the discretion of the investigator.  
3 Including intra-articular or peri-articular injections. Note that inhaled corticosteroids as well as corticosteroid drops in the eye or 
ear or nasal sprays are permitted. 
4 Mild to moderate topical corticosteroids are allowed only during the screening period if used only on the face, scalp, hands and 
feet and/or genitoanal area and if not used during at least 12hrs preceding the randomization visit 
5 Topical corticosteroids and other topical treatments will be allowed after Week 12 Visit only if (all must  apply):  
•medication was started after the Week 12 visit was completed;  
•medication was used for 14 consecutive calendar days or less; 
•medication was used for an indication other than psoriasis and not on the area affected with psoriasis. 
6 If the subject received a live vaccination during the study, the subject must discontinue study treatment.  
 
Exposure to light 
Subjects need to be advised to limit exposure to ultraviolet (UV) light (including sunbathing and/or use of UV tanning devices) during the study to avoid possible effect on psoriasis. 
5.5.9 Emergency breaking of assigned treatment code  
Not Applicable as treatment  is open label.  
5.6 Study  completion and discontinuation  
5.6.1 Study completion and post -study treatment  
A subject will be considered to have completed the study when the subject has completed the 
Wee
k 224 visit as per the protocol. For subjects who discontinue prior to this, the study 
completion corresponds to the last study visit of the subject or contact of the site with 
custodian/subject.  Study completion  for the study will occur  when  all randomized  subjects have 
completed the study as stated above. 
The investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the  study, or must refer them for appropriate ongoing care. 

Novartis  Confidential  Page  37 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
5.6.2 Discontinuation of study treatment  
Discontinuation of study treatment for a subject  occurs when  study drug is stopped earlier  than 
the protocol planned duration, and can be initiated by either the subject/custodian or the 
investigator.  
The investigator must discontinue study treatment for a given subject if, on balance, he/she 
believes that continuation would negatively impact the risk/benefit of trial participation.  
Study treatment must be discontinued under the following circumstances:  
• Subject/custodian’s  wish 
• Withdrawal  of consent  
• Pregnancy (see Section 6.5.8 and Section 7.6) 
• Ongoing use of prohibited  treatment as per  recommendations in Table  5-3 
• Emergence of the following  AEs:  AEs that in the judgment of the investigator/qualified 
site staff, taking into account the subject’s overall status, prevent the subject from continuing study treatment, for example sepsis, or newly occuring or worsening Inflammatory Bowel Disease, including Crohn’s disease and ulcerativ e colitis.  
• Any laboratory abnormalities  that in the judgment of the investigator/qualified  site staff, 
and taking into consideration the subject’s overall status, prevents the subject from continuing study treatment. 
• Live vaccination  
• Any situation  where  study participation  results  in a significant  risk to subject’s  safety  
If discontinuation of study  treatment  occurs,  the subject should NOT  be considered  withdrawn 
from the study. If the subject discontinued study treatment within the treatment period, the subject should return to the clinic after discontinuation of study drug, for Week 208 and Follow-up visits (Week 212, Week 216 and Week 224). 
At the time  of the study treatment discontinuation visit, if it has been approximately  4 weeks 
post last dose of study treatment  then the assessments described  at Week  208 visit in Table  6- 
2 should be completed and recorded in the eCRF. 
If it has not been approximately  4 weeks post last dose of study treatment at the time of the 
study treatment discontinuation visit,  then the subject  should be scheduled to return  4 weeks 
post last dose for their Week 208 visit. 
The investigator must determine the primary reason for the subject’s premature 
discontinuation of study treatment and record this along with the date treatment was stopped 
on the eCRF page. The investigator must also contact the IRT to register the subject ’s 
discontinuation from  study  treatment.  As mentioned  above if subjects discontinues treatment 
early, subject is expected to perform the visits of the treatment –free follow up period. 
If the subject cannot or is unwilling to attend any  further visit(s), the site staff should maintain 
regular telephone contact with the custodian/subject to obtain at least information on adverse 
events or concomitant medication. This telephone contact should preferably  be done according 
to the study visit schedule. 

Novartis  Confidential  Page  38 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Discontinuation from  the treatment -free follow -up period  
Subsequently to the Week  208 visit the subject  will be expected  to return  to the site and 
perform all visits of the treatment- free follow -up period as indicated in Table 6 -2. 
If premature withdrawal occurs for any reason in the treatment- free period (follow -up period, 
Week  208- Week 224), the subject is expected  to return to the site and perform all assessment 
of visit EOF  /Week  224 (see Table  6-2).  The investigator must  make every  effort to determine 
the primary rea son for a subject’s premature withdrawal from the study and record this 
information on the  relevant eCRF).  
Of note, if subjects start another systemic anti psoriatic  treatment during follow  up, they do not 
need to continue with the remaining follow -up visits but they  will be expected to return to site 
after the start of the systemic treatment and perform Week 224 visit.  
5.6.3 Withdrawal of informed consent  
Custodians/subjects may voluntarily withdraw consent for participation in the study for any 
reason at any time. Withdrawal of consent from the study is defined as when a subject:  
• Does not want to participate in the study  anymore  
and 
• Does  not want  any furth er visits  or assessments  
and 
• Does  not want  any further study related contacts  
and 
• Does  not allow  analysis of already  obtained biologic material 
In this situation, the investigator must make every effort (eg telephone, e -mail, letter) to 
determine  the primary  reason  for the subject’s  decision to  withdraw his/her  consent and  record 
this information.  
Study treatment must be discontinued and no furthe r assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact the subject are not allowed unless safety findings require communicating or follow -up. 
All efforts should be m ade to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as detailed in the assessment table below.  
5.6.4 Loss to follow -up 
For subjects whose status is unclear because they fail t o appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by documenting in the source documents steps taken to contact the subject, eg dates of telephone calls, registered letters, etc.  

Novartis  Confidential  Page  39 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
5.6.5 Early  study termination by the sponsor  
The study can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit risk assessment of participating in the study, practical reasons, or for 
regulatory  or medical  reasons (including  slow enrolment).  Should this be necessary,  the subject 
must be seen as soon as possible and treated as a prematurely discontinued subject. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration  is given to the protection of the subject’s  interests.  The investigator will 
be responsible for informing the Institutional Review Board/Independent Ethics Committee (IRBs/IECs) of the early termination of the trial.  
 
Visit  schedule and assessments  
Subjects should be seen for all visits on the designated day or as closely as possible to the original planned visit schedule. 
During the COVID-19 pandemic or similar major  health  care disruption that limits  or prevents 
on-site study visits, alternative methods of providing continuing care may be implemen ted 
Phone calls, virtual contacts (e.g. teleconsult) or visits by  site staff or home nursing service to 
the participant´s  home depending on local  regulations and capabilities,  can partially  replace on- 
site study visits, for the duration of the pandemic/ health care disruption until it is safe for the 
participant to visit the site again. These contacts should occur on or around the scheduled visit dates (or more frequently if needed). Events qualifying for being reported in CRF should be entered as appropriate. Every effort should be made to complete all study visit assessments feasible per protocol. Special effort should be made to conduct the scheduled EOT and EOF visit on site. If it is not feasibl e to conduct the EOT  and EOF  visit on- site, at least phone contact 
or if possible visits to the patient´s home by site staff as mentioned previously should be attempted.  
Screening will be flexible in duration and will last up to a maximum of 4 weeks. During this time, the custodian(s) and subject will sign first the informed consent and assent form respectively, subject will then be evaluated for eligibility and will have all screening visit assessments done as indicated in Table 6-1. 
Table 6 -1 and Table 6 -2 list all study  assessments and indicate with an “x” at which visits the 
assessments are performed.  
If for any reason the subject is a screen failure, the subject may be rescreened. There is no restriction on the number o f times a potential subject may  be rescreened or on how much time 
must pass from the date of screen failure and the date of rescreening.  
If a subject  rescreens for the study, then the custodian/subject must sign a new ICF/assent  form 
and be issued  a new subject  number prior to any screening  assessment  being conducted for the 
subject under the new screening  subject  number. For all subjects,  the investigator/qualified  site 
staff will record if the subject was rescreened on the eCRF and any applicable screening numbers the subject was issued prior to the current screening number. 
The date of  the new  informed  consent signature must be entered  on the eCRF  to correspond to 
the new screening  subject number. Informed  Consent for a rescreened  subject  must  be obtained 

Novartis  Confidential  Page  40 
Protocol  No. CAIN457A2311  Clinical  Trial Protocol  Amendment  (Version  01) Clean   
prior to performing any study related  assessment  or collecting  any data for the Screening  Visit. 
For rescreening, all screening assessments must be p erformed as per protocol, except for the 
tuberculosis (TB) work up, if applicable, if performed not more than 12 weeks before 
randomization.  
If the date of a TB work up is less than 12 weeks from the projected randomization date, then it is not required that the TB work up be repeated. However, the subject must repeat the tuberculosis test performed by the central laboratory.  
At the discretion  of the investigator,  laboratory  assessments at randomization visit need not be 
performed if screening laboratory assessments were performed within 7 days from randomization.  
During the treatment  period, subjects  may be seen at an unscheduled visit,  eg if they experience 
deterioration of psoriasis, or AEs that in the opinion of the investigator need intervention or repeated laboratory testing.  During these unscheduled visits, study treatment will NOT be 
administered.  The assessment(s) performed at an unsched uled visit are at the investigator’s 
discretion.  
Suggested  order of assessments:  
Suggested guidelines for conduct of the visit assessments (as applicable) are below:  
• Subject to complete  CDLQI  at the study site prior to any study  assessments.  
• Investigator to complete  investigator assessments:  
• IGA mod 2011  
• PASI  
• Review  of CDLQI  data 
• Physical  exam  
• All remaining study visit procedures (eg, AE and concomitant medication collection, laboratory  sample  collection, vital signs measurements,  etc) must be completed  and results 
reviewed by the investigator or qualified designee prior to study treatment dosing. 
• Enter  PASI  data into the source data worksheets and perform calculations  as needed 
BEFORE contacting IRT at randomization Visit.  
• Contact IRT to register the  subject visit,  as applicable  
• Administration  of study treatment,  as applicable  

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  41 
Protocol  No. CAIN457A2311   
 
Table 6-1 Assessment  schedule (Year  1) 
 
Period  Scr Treatment Year 1 
Week  -4-Ra Day 1 (R) 1 2 3 4 8 12 13 14 15 16 24 32 40 48 52 
Day -28-Ra 1 (R) 8 15 22 29 57 85 92 99 106 113 169 225 281 337 365 
Obtain informed consent1 x                 
Subject demographics  x                 
Inclusion/ exclusion2 S S                
Psoriasis history/prior therapies  x                 
Medical  history  and prior medications  x                 
Concomitant medications3 update as necessary  
Surgeries  and non-drug procedures  update as necessary  
Physical Exam S S S S S S S S    S S S S S S 
Height4 x x    x x x    x x x x x x 
Weight  x x    x x x    x x x x x x 
Vital signs (BP & pulse)  x x x x x x x x    x x x x x x 
Labs: Hematology6 x x  x  x x x    x x x x x x 
Blood chemistry6, Urinalysis(local)  x x    x x x    x x  x  x 
Tuberculosis test7 x                 
Serum  pregnancy  test(in females  of 
childbearing potential) 6 x                 
Urine  Pregnancy  test8(local;  in females  of 
childbearing potential)   
x      
x     
x    
x 
ECG  (standard  12-lead)  x       x     x    x 
Blood sample for  immunogenicity(pre-dose)9  x          x x    x 
Blood sample for PK  (pre-dose)9  x    x  x x x x x x    x 
PASI  x x x x x x x x    x x x x x x 
IGA mod 2011 x x x x x x x x    x x x x x x 

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  42 
Protocol  No. CAIN457A2311   
 
Period  Scr Treatment Year 1 
Week  -4-Ra Day 1 (R) 1 2 3 4 8 12 13 14 15 16 24 32 40 48 52 
Day -28-Ra 1 (R) 8 15 22 29 57 85 92 99 106 113 169 225 281 337 365 
CDLQI10  x    x x x     x    x 
(Serious) Adverse event assessment  update as necessary  
Randomization via IRT  x11                
Data entry of weight into IRT12  x      x    x x x x x x 
Administration of study drug13  x x x x x x x    x x x x x x 
Contact IRT x x x x x x x x    x x x x x x 
Scr= screening,  R=randomization,  PK=pharmacokinetics,  ECG=Electrocardiogram,  CDLQI=  children’s  dermatology  life quality  index,  IRT=Interactive 
response technology,  
X=assessment  entered or transferred into the clinical  database.  S= assessment  only recorded  in source  
a Before  randomizing  the subject,  the site must  ensure that all assessments  of the screening visit have been  performed,  all lab results  are available and 
subject is eligible. Special attention must be given to tuberculosis testing as results take longer to be available.  
1 Apart  from the Informed consent  for this study  signed  by parent(s)  /legal  representatives,  assent  form will be completed as appropriate  by the pediatric 
subjects.  
2 These assessments  are supported by and are stored  with the source documentation.  However,  data regarding  to which  inclusion/exclusion criteria  are 
met are captured on the appropriate eCRF  
3 Information on Topical  Corticosteroid  medication,  that a subject  may use, is entered in the concomitant  medications -topical  corticosteroids  eCRF  
4 Measured standing and barefoot,  using the same  stadiometer.  
  
6 Samples  will be shipped to and analyzed by the central  lab. At the discretion of the investigator,  laboratory  assessments  need not to be performed 
again at Day 1- Randomization (R) visit if screening labs were performed within 7 days from randomization.  
7 If the first tuberculosis central lab test is indeterminate, the investigator may  choose to perform a second test (as part of an unscheduled visit) or refer 
the subject  for tuberculosis  workup per local guidelines.  If the result  of any tuberculosis  central  lab test is “positive”  or the results  of two sequential  tests 
are “indeterminate”,  the subject  must  be referred to have a tuberculosis  workup  per local guidelines  (if no workup within  12 weeks  prior to randomization 
is available).  The subject will not be eligible for randomization if active tuberculosis is present or if latent tuberculosis is present and is untreated as per 
local guidelines.  
8 Urine  pregnancy  test will be performed  locally.  If there is a positive  urine pregnancy  test, study  treatment  must  be withheld and a serum  pregnancy  test 
done at the same visit. Pregnancy tests will be performed in female subjects of child bearing potential, i.e. those who have started menstruation and/or 
are of age 12 or older.  

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  43 
Protocol  No. CAIN457A2311   
 
9 Samples  shipped by the sites will be stored at the central  laboratory  and then shipped to reference laboratories  for analysis.  Each  PK and IG blood 
sample should be collected pre -dose between Day 1 (Randomization) and Wk 52.  
10 CDLQI  will no longer  be completed once  subjects  reach  18 years  of age 
11 At Day 1- Randomization  the PASI  Score  and BSA must  be calculated by appropriate  site staff prior to contacting IRT. The investigator  must  ensure 
subject meets all eligibility criteria before contacting IRT to randomize the subject.  
12 For every  visit (including unscheduled),  weight  measured at that visit will be entered into IRT. 
13 Secukinumab will be dispensed at site visits. After Week 16 and until  Week 52 monthly treatment which occurs outside the site visits, may be 
administered at home every 4 weeks, either by subject (self -injection  is allowed for subjects ≥ 12 years ) or parent/caregiver. In case subject or parent 
does not feel confident in performing home administrations subjects will be allowed to continue to perform drug administrations at site. These home 
administrations  in the first year occur  at Wk 20, Wk 28, Wk 36,  Wk 44. During the COVID -19 pandemic,  or any other  pandemic,  study  medication may be shipped 
to the patient’s home and administration should be completed at the scheduled timepoints.  

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  44 
Protocol  No. CAIN457A2311   
 
Table 6-2 Assessment  schedule - Years 2-4 (continued) 
 
Period  Treatment  Period  (years 2-4)  Follow -up Periodb  
Unscheduled  d  
 
Week   
 
64  
 
76  
 
88  
 
104  
 
116  
 
128  
 
140  
 
156  
 
168  
 
180  
 
192  
208 
EOT  
 
212  
 
216  
224 
EOF 
Day 449 533 617 729 813 897 981 1093 1177 1261 1345 1457 1681 1709 1765  
Concomitant medications1 Update as necessary  x 
Surgeries and non -drug procedures  Update as necessary  x 
Physical  Exam  S S S S S S S S S S S S s  S S 
Height2 x x x x x x x x x x x x x  x x 
Weight  x x x x x x x x x x x x x  x x 
Vital signs (BP & pulse)  x x x x x x x x x x x x x  x x 
Hematology4 x x x x x x x x x x x x x  x x 
Blood  Chemistry4, Urinalysis  (local)  x x x x x x x x x x x x x  x x 
Urine  Pregnancy test (local;  in females  of childbearing 
potential)5  
S S S S S S S S S S S S   S S 
ECG  (standard  12-lead)     x  x  x  x  x   x x 
Blood sample for IG6    x    x    x   x x7 
Blood sample for PK6    x    x    x   x x7 
PASI  x x x x x x x x x x x x x x x x 
IGA mod 2011  x x x x x x x x x x x x x x x x 
CDLQI8 x x x x x x x x x x x x    x 

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  45 
Protocol  No. CAIN457A2311   
 
Period  Treatment  Period  (years 2-4)  Follow -up Periodb  
Unscheduled  d  
 
Week   
 
64  
 
76  
 
88  
 
104  
 
116  
 
128  
 
140  
 
156  
 
168  
 
180  
 
192  
208 
EOT  
 
212  
 
216  
224 
EOF 
Day 449 533 617 729 813 897 981 1093 1177 1261 1345 1457 1681 1709 1765  
(Serious) Adverse event assessment  Update as necessary  x 
Data  entry of weight into IRT9 x x x x x x x x x x x      
Contact IRT x x x x x x x x x x x x     
Administration of Study Drug10 x x x x x x x x x x x      
End of Treatment             x     
Study completion                x  
R=randomization,  PK=pharmacokinetics,  ECG=Electrocardiogram,  CDLQI=  children’s  dermatology life quality  index,  IRT=Interactive  response technology,  
X=assessment entered or transferred into the clinical database.  S= assessment  only recorded in source  
a During EOT visit, subjects  will have their last assessments performed for treatment  period.  This visit will also be performed for all subjects  who will discontinue early  the 
treatment period.  
b Follow -up assessments  are to be conducted  for subjects  who complete treatment  period  and for subjects  who discontinue study  treatment  early  
c EOF assessments are to be conducted for subjects who  complete treatment  free follow up period and for subjects who discontinue  this period early  
d The assessments performed  at an unscheduled visit are at the investigator’s discretion  
1Information on Topica l Corticosteroid medication,  that a subject  may use, is entered in the concomitant  medications - topical  corticosteroids  eCRF  
2 Measured standing and barefoot,  using the same calibrated stadiometer,  
 
4 Samples  will be shipped to and analyzed by the central lab. 
5If there is a positive  urine pregnancy  test, study  treatment  must be withheld and a serum  pregnancy  test must be done at the same visit and sent to central  lab. 
Pregnancy tests will be performed in female subjects of child bearing potential, that is those who have started menstruation and/or are of age 12 or older.  
6 Samples  shipped by the sites will be stored  at the central  laboratory  and then shipped to reference laboratories  for analysis. Each PK and IG sample should be collected 
pre-dose for Week 52 to Week 208.  
7 An unscheduled IG and/or  PK sample is collected only to replace an IG or PK sample not taken at a regular  scheduled visit. In case unscheduled IG sample is taken, 
there should always be a matching unscheduled PK sample taken at the same time point.  
8 CDLQI  will no longer  be completed once subjects  reach 18 years  of age 

Novartis  
Clinical  Trial Protocol  Amendment  (Version  01) Clean  Confidential  Page  46 
Protocol  No. CAIN457A2311   
 
9 For every  visit, the weight  measured at that visit will be entered into IRT 
10 Secukinumab will be dispensed at site visits. Between site visits, study medication will be administered every 4-weeks at home either by the subject (self -injection is 
allowed for subjects ≥ 12 years) or parent/caregiver until Week 204. In case subject or parent/caregiver does not feel confident in performing home administrations 
subjects  will be allowed  to continue to perform  drug administrations  at site. Home administrations  in the years  2-4 occur at Wk 56, Wk 60, Wk 68, Wk 72, Wk 80, Wk 84, 
Wk 92, Wk 96, Wk 100, Wk 108, Wk 112, Wk 120,  Wk 124, Wk 132, Wk 136, Wk 144, Wk 148, Wk 152, Wk 160, Wk 164, Wk 172,  Wk 176,  Wk 184,  Wk 188, Wk 196,  
Wk 200, Wk 204. During the COVID -19 pandemic,  or any other  pandemic , study  medication may be shipped to the patient’s  home and administration should be 
completed at the scheduled timepoints.  

Novartis  Confidential  Page  47 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
 
6.1 Information  to be collected on screening failures  
All subjects who sign the informed  consent  but discontinue prior  to randomization  at Day 1 are 
considered to be screen failures.  
If a subject discontinues prior to randomization, the IRT provider must be notified within 5 
days, and the reason for the subject not being randomized will be entered in the respective Disposition eCRF. The Screening visit date, the Demography eCRF, the Informed Consent eCRF, the Inclusion/Exclusion eCRF, and the subject rescreening eCRF must be completed. The AE eCRF should be completed for any SAEs that occurred during the screening period. Adverse events that are not SAEs  will be followed by the investigator  and collected  only in the 
source data. The Death eCRF should be completed in the case of a death during the screening period. The withdrawal of consent eCRF must be completed if consent was withdrawn during the screening period before the subject was randomized.  
6.2 Subject  demographics/other  baseline  characteristics  
All Baseline assessments should be performed prior to first study treatment administration. 
These may be in the screening period (eg demographics) or at the Randomization Visit eg 
patient reported outcomes (PROs), depen ding on the assessment. 
6.2.1 Demographics 
Data  to be collected  on all subjects include: age, sex, race,  and ethnicity).  
6.2.2 Psoriasis medical history / Previous psoriasis therapy  
Disease history will be collected at the screening visit. The information to be collec ted and 
entered in the Psoriasis History eCRF and Prior Psoriasis Therapies eCRF includes the following:  
• The date of first diagnosis of plaque psoriasis  (by a physician)  
• The previous treatments  of psoriasis (including previous use systemic therapies,  biologic 
therapies, as well as phototherapy and/or photo chemotherapy or topical use) and the reason for discontinuation of each therapy  
• The presence of psoriatic  arthritis  and the date of first diagnosis (by a physician)  
6.2.3 Relevant medical histor y / current medical  conditions  
Relevant medical history and current medical conditions, not including psoriasis or psoriatic arthritis,  prior  to signing of the informed  consent  will be recorded  in the Medical  History  eCRF. 
Whenever possible, diagnoses and not symptoms will be recorded. 
Significant findings that are observed after the subject has signed the informed consent form 
and that meet the definition of an AE must be recorded in the AE eCRF.  
Investigators will have the discretion to record abnormal test findings on the medical history CRF whenever in their judgment, the test abnormality occurred prior to the informed consent signature.  

Novartis  Confidential  Page  48 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.2.4 Determination of Tuberculosi s status  
Determination of tuberculosis (TB) status will be required before administration of study 
treatment and should be performed  as defined by local  guidelines. TB status must be determined 
by medical history, signs, symptoms and TB central lab testing. Any significant findings will be recorded  in the relevant TB assessment eCRF  and the Medical History  eCRF, as necessary.  
A central  lab testing  will be performed  to assess the TB status at screening  for all subjects.  This 
test will only be used to determine subject’s eligibility for the trial. The test will be used to screen the subject population for latent tuberculosis infection (Doherty et al 2008).  
This blood- based assay is specific for Mycobacterium tuberculosis and is not influenced by 
previous Bacillus  Calmette -Guérin  vaccination  or exposure to other Mycobacteria species.  This 
test, in contrast  to the purified  protein derivative (PPD)  skin test, is also insensitive to a booster 
effect since the subject is not exposed to the vaccine. The assay measures the production of interferon -gamma and presents it relative to a negative and a positive control sample. Further 
information is available in Manuel and Kumar (2008) . 
The tuberculosis assay  test will be supplied by the central  laboratory.  Details  on the  collection, 
shipment of samples and reporting of results by the central laboratory are provided to investigators in the laboratory manual. 
Refer  to Figure  6-1 for guidance on subject eligibility  with respect  to TB testing. The results  of 
a workup for a subject  with a positive or indeterminate  test must  be recorded  on the Tuberculosis 
assessment eCRF.  
• If the test result is negative , the subject  may be randomized.  
• If the test result is positive , the investigator should perform workup for the test result as 
per local procedures. If a TB workup was conducted prior to the screening the subject, 
results of the workup can be used to assess eligibility  if the workup was conducted within 
12 weeks prior to randomization. 
• Subject positive for latent  TB per workup may be randomized to the trial if sufficient 
treatment has been initiated according to local routine clinical practice and will be maintained for the prescribed duration. 
• Subjects positive for active TB per workup are not eligible for the study.  
• Subjects negative for TB (
 no signs of latent  or active  TB) per workup may be 
randomized to the trial.  
• If the test result is indeterminate , the investigator may repeat the test once or may 
proceed directly to perform workup for the test result as per local procedures. This action is at the discretion of the investigator. If a TB workup was conducted prior to the screening  the subject,  results  of the workup can be used to assess eligibility  if the workup 
was conducted within 12 weeks prior to randomization. 
• If the s
econd test  is negative, the subject  may be randomized. 
• If the second  test is positive or indeterminate , the investigator should perform workup 
as per local  guidelines. Subject positive for latent TB per workup may be randomized 
to the trial if sufficient treatment has been initiated according to local routine clinical practice and will be maintained for the prescribed duration. The subject  will not be 

Novartis  Confidential  Page  49 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
eligible  for randomization  if “active tuberculosis is present” or “latent  tuberculosis is 
present” and is untreated per local guidelines.  
• Subjects negative for  TB per workup (no signs of latent  or active TB)  may  be 
randomized to the trial if the workup was conducted 12 within  weeks prior to 
randomization.  
If eligibility  is being assessed with only 1 test result and a TB workup (i.e., no second TB test 
will be performed), the TB test to assess eligibility must have  been done via the central 
laboratory for the study within the screening period (within 4 weeks prior to randomization) 
and TB workup will only be considered if it was completed within 12 weeks prior to randomization.  

Novartis  Confidential  Page  50 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Figure 6-1 Tuberculosis  screening flowchart  
 

Novartis  Confidential  Page  51 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.2.5 Other  baseline characteristics  
Baseline characteristic data to be collected on all subjects include (all labs are central except 
where indicated): 
ECG,  vital signs; hematology; clin ical chemistry;  local  urinalysis; immunogenicity; PK; PASI; 
IGA mod 2011; CDLQI.  A seru
m pregnancy test will  be performed  for females  of child  bearing 
potential or of at least 12 years of age at screening.  
6.3 Treatment  exposure and compliance 
All doses of study treatment administered will be recorded on the appropriate Dosage 
Administration Record eCRF page. Information on drug dispensing, administration, 
accountability  will be collected  in drug accountability logs and other documents as appropriate. 
For drug administrations at home subject will record relevant information at home which will then be transcribed at the corresponding documents at site including Dosage Administration Record eCRF page,  
Subject compliance to the study treatment should be assessed  by qualified  site personnel at each 
study visit using the study kits and documentation regarding study treatment dispensation and administration.  
Site compliance will also be assessed  continuously during the conduct of the study by Nova rtis 
study personnel using medication kits and the corresponding documentation. 
6.4 Efficacy  
All efficacy  assessments should be performed  prior  to administration  of study  treatment.  There 
are two co -primary  efficacy  variables in this study: PASI 75 response and IGA mod 2011 0 or 
1 response. 
The following order should be applied  when  performing the efficacy  assessments during study 
visits: 
• Investigator’s  Global Assessment  (IGA  mod 2011; scale from  0 – 4) 
• Psoriasis  Area  and Severity  Index (PASI; score from  0 – 72) 
  
6.4.1
 Invest
igator  Global  assessment  (IGA  mod  2011)  
The IGA mod 2011 will be conducted for overall psoriatic  disease  as indicated in Table  6-1 and 
Table 6 -2. It is recommended that the same evaluator conducts the efficacy assessment 
throughout t
he study whenever possible. 
The IGA mod 2011 rating  scale for overall  psoriatic  disease is shown in Table 6-3 below.  
The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II studies in collaboration with health authorities, in particular the FDA. The explanations/descriptions of the points on the scale have been improved to ensure appropriate differentiation between the points. 

Novartis  Confidential  Page  52 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
The IGA mod 2011 used in this study is static, ie, it refers exclusively  to the subject’s disease 
state at the time of the assessments,  and does not attempt  a comparison  with any of the subject’s 
previous disease states, whether at baseline or at a previous visit.  
The IGA mod 2011 score will be recorded in the eCRF.  
Table 6-3 IGA mod 2011 scale  
 
 
0 Clear,  No signs  of psoriasis.  Post-inflammatory  hyperpigmentation may be present  
1 Almost  clear - Normal  to pink coloration of lesions;  no thickening;  no to minimal  focal 
scaling  
2 Mild- Pink to light red coloration;  just detectable to mild thickening;  predominantly  fine 
scaling  
3 Moderate - Dull bright  red, clearly  distinguishable erythema;  clearly  distinguishable to 
moderate thickening; moderate scaling  
4 Severe - Bright  to deep dark red coloration;  severe  thickening with hard edges;  severe  / 
coarse scaling covering almost all or all lesions  
Based  on this scale,  a subject  will be eligible  to participate  in the study if the subject  has an IGA 
mod 2011 score at baseline of 3 or 4. 
Based on this scale, a subject will be considered an IGA mod 2011 0 or 1 responder if the 
subject achieves a score  of 0 or 1 and improved  by at least 2 points on the IGA mod 2011 scale 
compared to baseline.  
6.4.2 Assessment  of total  body surface area (BSA)  and p soriasis area safety 
index (PASI)  
The investigator or trained qualified designee will complete the PASI assessment as indicated in Table 6 -1, Table 6 -2. Whenever possible, the same evaluator should perform this efficacy 
assessment at all visits.  
The total BSA  affected  by plaque- type psoriasis  will be estimated  from the percentages  of areas 
affected, including head, trunk, upper limbs and lower limbs (see below for full details of the PASI assessment). The following calculations will be done: Each reported percentage will be multiplied by its respective body region corresponding factor (head = 0.1, trunk = 0.3, upper limbs  = 0.2, lower  limbs  = 0.4). The resulting  four percentages  will be added up to estimate  the 
total BSA affected by plaque- type psoriasis.  
A PASI score ( Fre
 driksson and Petterson 1978, Weisman et al 2003, Gottlieb et al 2005) will 
be derived as indicated  in Table  6-4. The head, trunk, upper limbs  and lower  limbs  are assessed 
separately  for erythema,  thickening (plaque elevation,  induration),  and scaling  (desquamation). 
The average  degree of severit y of each sign in each of the four body regions is assigned  a score 
of 0-4. The area covered  by lesions on each body region is estimated  as a percentage of the total 
area of that particular body region. Further practical details help the assessment:  
• The neck  is assessed  as part of the head.  
• The axillae and groin are assessed as part of the trunk.  
• The buttocks  are assessed  as part of the lower  limbs.  

Novartis  Confidential  Page  53 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
• When  scoring  the severity  of erythema,  scales should not be removed.  
Table 6-4 PASI scoring system  
 
Body  region  Erythema (E) Thickening (I) 
(plaque 
elevation,  
induration)  Scaling (D) 
(desquamation)  Area  score (A) 
(based  on true area %)* 
Head (H)† 0=none 0=none 0=none 0 = no involvement  
1= slight  1= slight  1= slight  1 = >0-<10%  
2= moderate  2= moderate  2= moderate  2 = 10-<30%  
3= severe  3= severe  3= severe  3 = 30-<50%  
4=very  severe  4=very  severe  4=very  severe  4 = 50- <70%  
   5 = 70-<90%  
   6= 90 -100%  
Trunk  (T)‡ 0=none 0=none 0=none 0 = no involvement  
1= slight  1= slight  1= slight  1 = >0-<10%  
2= moderate  2= moderate  2= moderate  2 = 10-<30%  
3= severe  3= severe  3= severe  3 = 30-<50%  
4=very  severe  4=very  severe  4=very  severe  4 = 50- <70%  
   5 = 70-<90%  
   6= 90-100%  
Upper  limbs  (U) 0=none  0=none  0=none  0 = no involvement  
1=slight  1=slight  1=slight  1 = >0-<10%  
2=moderate  2=moderate  2=moderate  2 = 10-<30%  
3=severe  3=severe  3=severe  3 = 30-<50%  
4=very  severe  4=very  severe  4=very  severe  4 = 50- <70%  
   5 = 70-<90%  
   6 = 90-100%  
Lower  limb (L)§ 0=none 0=none  0=none  0 = no involvement  
1=slight  1=slight  1=slight  1 = >0-<10%  
2=moderate  2=moderate  2=moderate  2 = 10-<30%  
3=severe  3=severe  3=severe  3 = 30-<50%  
4=very  severe  4=very  severe  4=very  severe  4 = 50- <70%  
   5 = 70-<90%  
   6 = 90-100%  
* Percentage (not score)  of body  region (not whole  body)  affected  will be entered in the eCRF  
† Neck  is assessed  as part of the Head (H) body  region.  
‡ Axillae  and groin are assessed  as part of the Trunk  (T) body  region.  
§ Buttocks  are assessed  as part of the Lower  limbs  (L) body  region.  
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated using the formula:  
PASI=0.1  (EH+IH+DH)AH+0.2(EU+IU+DU)AU+0.3(ET+IT+DT)AT  +0.4(EL+IL+DL)AL  

Novartis  Confidential  Page  54 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
The keys for the letters  are provided in Table  6-4. 
PASI  scores  can range from  a lowest  value of 0, corresponding to  no signs of psoriasis,  up to  a 
theoretic maximum of 72.  
The investigator or qualified designee is responsible for evaluating the subject and collecting 
the PASI  components, scoring signs and total regional area.  The PASI  data will be entered  into 
the PASI eCRF.  
Based  on PASI,  to be eligible,  a subject  must have a score of 12 or more  at the Randomization 
Visit.  
Based  on total BSA,  to be eligible,  a subject must have 10% or more  total BSA  involved at the 
Randomization Visit.  
Only  if the above eligibility  criteria  and all other  eligibility  criteria  are fulfilled  should site 
contact IRT at the Randomization Visit to randomize the subject.  
Definitions of efficacy variables based on PASI  
The following definitions  are used in this study (see CHMP  guidelines for psoriasis  
(CHMP/EWP/2454/02 2004)) : 
PASI  75 response: subjects achieving  ≥ 75% improvement (reduction) in PASI  score compared 
to baseline are defined as PASI 75 responders 
PASI  90 response: subjects achieving  ≥ 90% improvement (reduction) in PASI  score compared 
to baseline are defined as PASI 90 responders 
PASI  100 response / remission : complete  clearing  of psoriasis  (PASI=0)  
  
6.4.4
 Appropriateness of efficacy assessments  
The PASI score, the assessment of the severity of the psoriasis symptoms and the extent to 
which the subject’s body area is affected by the disease, is considered acceptable by health authorities (CHMP guideline on the treatment of psoriasis -CHMP/EWP/2454/02 2004) to 
assess efficacy in conjunction with Investigator’s Global Assessment  (IGA).  

Novartis  Confidential  Page  55 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.5 Safety 
All blood draws  and safety  assessments should be done prior to study treatment administration. 
Appropriate safety assessments (eg, evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered.  
During the COVID- 19 pandemic or similar major health care disruption that limits or preven ts 
on-site study visits,  phone calls,  virtual  contacts (e.g. teleconsult),  or visits  by site staff or home 
nursing service depending on local regulations and capabilities may occur  on or around 
scheduled protocol visit dates (or more frequently if needed). This will be done for safety 
monitoring and discussion of the  subject´s health status until the subje ct can again visit the 
site. Case report forms  (e.g. AEs,  concomitant medications, procedures and non-drug therapies) 
should be updated as appropriate. 
6.5.1 Physical  examination 
A physical examination, including general  appearance,  skin, neck,  eyes,  ears, nose, throat,  lungs, 
heart, abdomen, back, lymph nodes, and extremities, and vascular and neurological systems 
will be performed  as indicated  in Table  6-1, Table  6-2. Investigator should pay special  attention 
to any signs or symptoms of potential skin or mucosal candida infections. 
If indicated,  based  on medi cal history  and/or symptoms, additional exams  will be performed  at 
the discretion of the investigator.  
If possible, assessments for an individual subject should be performed by the same member of 
the study site staff throughout the study. Information for a ll physical  examinations must be included in the source documentation  at the 
study site. Significant findings that are present prior to the screening visit must be included in 
the Medical History  screen on the subject’s eCRF. Significant findings made after the start of 
study (Day 1) that meet the definition of an adverse event must be recorded on the Adverse 
Event screen of the subject’s eCRF.  

Novartis  Confidential  Page  56 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.5.3 Vital signs  
Vital s igns (including blood pressure and pulse measurements) will be assessed at every 
scheduled visit as indicated in Table 6 -1, Table 6 -2. If possible, assessments should be 
performed by the same study site staff member throughout the study. 
After the subject  has been  sitting  for five minutes,  with back  supported and both feet placed  on 
the floor, systolic and diastolic blood pressure will be measured twice (measurements 
separated  by 1 to 2 minutes)  using a validated  device,  with a cuff that is appropriately  sized  for 
the subject’s arm circumference. The average of the two measurements will be entered on the 
Vital Signs eCRF.  
The Recommendations for the dimensions of Blood Pressure Cuff Bladders are noted in the following table.  
Table 6-5 Recommended Dimensions for Blood Pressure Cuff Bladders  
 
 Width  [cm] Length [cm] Maximum Arm 
Circumference  [cm]*  
Newborn  4 8 10 
Infant  6 12 15 
Child  9 18 22 
Small  adult  10 24 26 
Adult  13 30 34 
Large  adult  16 38 44 
*calculated  so that the bladder  can encircle  even  the largest  arm by at least  80% 
Source:  Feld and Corey  H (2007) : Hypertension in childhood,  Pediatric  in Review  28: 283-98 
Whether action needs to be taken to address notable vital signs will be decided by the investigator/qualified  site staff,  taking  into account  the overall  status  of the subject. No specific 
action is foreseen as part of the study protocol.  
6.5.4 Height and weight  
Height and body weight will be measured at visits as in Table 6 -1, Table 6 -2. Height 
measurements (in indoor clothing, but without shoes,  socks,  hats or hair accessories interfering 
with assessment) will be made using a stadiometer that is calibrated on a regular basis. Height measurements will be performed twice and the reported height will be the mean of the 2 
measurements.  
If possible, body weight assessments (in indoor  clothing, but without shoes) should be 
performed  by the same study site staff member and using the same scale throughout the study. 
The body weight recorded at Randomization (Day 1) will be used to categorize the subject 
population at randomization to receive the corresponding doses in the high dose and low dose secukinumab groups. 
6.5.5 Laboratory evaluations  
Subjects should avoid smoking within  the hour preceding  the blood draws. 

Novartis  Confidential  Page  57 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
A central laboratory will be used for analysis of all specimens listed below, unless noted 
otherwise.  Details on the collections,  shipment of samples and reporting of results by the central 
laboratory  are provided to investigators  in the laboratory  manual.  The blood volume drawn  will 
be adjusted for pediatric subjects and will be stated in the laboratory manual.  
During the COVID-19 pandemic or a major healthcare  disruption  that limits  or prevents  on-site 
study visits and central lab sampling, performing the safety  lab tests locall y will be allowed in 
case it is needed to check safety parameters. Depending on local regulations, technical 
capabilities and following any applicable training in the required process, qualified staff may 
visit the subject at home to draw blood/ urine samp les if needed to check safety parameters.  
Clinically notable values for key laboratory tests are defined in Section 13, Appendix 1. For 
identification of pediatric  abnormal values for all par ameters,  the laboratory manual must also 
be consulted. 
Whether action needs to be taken to address notable laboratory values will be decided by the 
investigator,  taking into  account the overall status of the subject.  No specific action  is foreseen 
as part of the study protocol. 
6.5.5.1 Hematology  
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(neutrophils including bands, lymphocytes, monocytes, eosinophils, basophils) and platelet count will be measured at scheduled study visits, as specified in Table 6 -1, Table 6 -2. 
6.5.5.2 Clinical chemistry  
Serum chemistry will include urea or BUN, creatinine, total bilirubin, AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, total protein, albumin, and uric acid. 
Serum  chemistry  will be measured  at scheduled  study visits  as specified  in Table  6-1, Table  6- 
2. 
6.5.5.3 Estimated GFR 
In addition estimated Glomerular Filtration Rate (eGFR) as per Schwartz et al (Schwartz et al  
2009) will be calculated and reported by  the Central Laboratory, whenever a serum creatinine 
is performed.  
The calculation is based on the following formula: 
eGFR (ml/min/1.73m
2) = 0.413 x height (cm)  / serum  creatinine  (mg/dl) 
Height will be provided by the site to the central lab. For eGFR, baseline value for the decrease from baseline criterion will be calculated as the 
average of values prior to the first dose ( i.e. screening and baseline values). 

Novartis  Confidential  Page  58 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.5.5.4 Urinalysis  
Urine  Dipstick (local)  
A midstream urine sample  (approximately  30 mL) will be obtained, in order  to avoid 
contamination with epithelial cells and sediments, and allow proper assessments. 
A semi -quantitative  ‘dipstick’ evaluation for the following  parameters will be performed: 
specific gravity, pH, glucose, protein, bilirubin, ketones, leukocytes and blood, micro  albumin.  
Urinalysis  will be measured  locally  at scheduled  study visits  as specified  in Table  6-1, Table  6- 
2. 
6.5.6 Electrocardiogram  (ECG)  
A standard 12-lead ECG will be performed  as indicated  in Table  6-1, Table  6-2. When  the ECG 
is performed at scheduled visits, the investigator will review and initial tracing, and store with 
the subject’s source documentation. All ECGs must be performed on the ECG machines provided to the study site. 
All ECGs  will be independently reviewed  by a central reader.  Instructions  for the collection  and 
transmission  of the ECGs  to the indep endent reviewer  will be provided in the ECG investigator 
manual.  
Even  though there  is no exclusion criterion  specifically  based  on the ECG,  the ECG performed 
at Screening  must be reviewed  for major abnormalities  before  dosing at the randomization visit. 
If the ECG findings are clinically relevant and would prevent the subject from participating in 
the study (taking into account the subject's overall status including medical history and concomitant medications), the subject should not receive treatment and should exit the study. If a clinically relevant abnormality is noted on the screening ECG it should be reported in the Medical  History  eCRF.  Clinically  relevant abnormalities  noted after the screening  ECG should 
be recorded as AEs.  
6.5.7 Immunogenicity  
Blood samples for immunogenicity (anti -secukinumab antibodies) will be taken pre -dose by 
direct venipuncture at the scheduled time points as indicated in Table 6 -1, Table 6 -2 and 
Appendix 2, Table 14-2. B
 lood samples (approximately 2 mL) will be collected into serum 
separator  tube (SST) tubes. The blood sample will be allowed to clot over a minimum of 30 
minutes at room temperature prior to harvesting of the serum. The serum will be obtained by centrifugation at approximately 2500 revolutions per minute (rpm) for 10 minutes, o r within 
sufficient time and speed to allow formation of a clear supernatant layer.  
Serum  samples will be split into 2 aliquots (labeled  plain  barrier polypropylene tubes)  and then 
stored (within 30 minutes of serum collection by centrifugation) at approximately -70˚C to - 
20˚C prior to shipment on dry ice to the central laboratory. Shipment of stored aliquots from the site to the central lab should be on a pre -specified basis. To the extent possible, the site 
should send  each aliquot of the  sample  to the c entral  laboratory separately.  The central  lab will 
ship aliquots of the samples on dry ice to the analytical laboratory as per agreement with Novartis. Immunogenicity samples will only be disposed of after approval by the Sponsor. 

Novartis  Confidential  Page  59 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
The actual  sample  collection  date and time will be entered  on the relevant  Blood collection  for 
IG eCRF. In case unscheduled IG samples are taken, matching PK samples must be taken as 
well.  
A laboratory manual will be provided by the central laboratory with detailed information on sample collection, sample handling and shipment. 
Tubes and labels  will be provided by the central  laboratory  with  study/sample type and sample 
number preprinted on the label. Further details on labeling of the immunogenicity samples can be found in App endix 2, Table  
14-2 . 
Sample stability  
Due to the nature of the immunogenicity response, no real stability data can be given for 
immunogenicity samples. 
The serum samples will be transferred on dry ice (enough dry ice to avoid thawing) from the 
central laboratory to the analytical laboratory at Novartis or a designated Clinical Research 
Organization (CRO).  
Immunogenicity analytical method  
An electrochemiluminescence based method will be used for the detection of potential anti - 
AIN457  antibody formation.  The detailed  method  description  to assess immunogenicity will be 
described in the bioanalytical raw data of the study and in the respective Bioanalytical Data Report (BDR).  
6.5.8 Pregnancy  and assessments of fertility  
Females of child -bearing potential are defined as all females physiologically capable  of 
becoming pregnant. This includes female  pediatric  subjects who are menarchal  or who become 
menarchal during the study. In this study pregnancy tests will be performed in female subjects 
who are menarchal  or become menarchal  during the study and/or are 12 years of age or older at 
the beginning or at any point during the study. Sites must ensure that pregnancy testing commences once any of these conditions are fulfilled.  
Serum pregnancy test will be performed for all females of child -bearing potential according to 
the schedule in Table 6 -1, Table 6 -2. 
During the COVID-19 pandemic or similar major  health  care disruption that limits  or prevents 
female subjects of childbearing potential or at least of 12 years of age for on -site study visits, 
urine pregnancy test kits may be shipped or provided directly to the subject. After appropriate 
instruction, patients can perform the urine pregnancy test at home at the time points specified in the protocol and report the result  to the site. It is important that patients perform the pregnancy 
test first and only if the test result  is negative,  they then should proceed with the administration 
of the study drug. 
A communication process should be established  with the subject  so that the site is informed  of 
the pregnancy test results.  

Novartis  Confidential  Page  60 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
All menarchal  girls and their parents/custodians should be informed  about the potential risks  of 
pregnancy and the need  to prevent pregnancy during the study. It is important to be sensitive  in 
introducing this issue, as understanding and comprehension of puberty, sexual activity, 
pregnancy and contraception is influenced by age, as  well as factors such as precocity, socio - 
educational economic and familial background. These discussions with the subject and her parents/custodians are therefore best performed by investigators familiar with the pediatric subject and her family  and should  be guided by requirements  of the local  regulatory  authorities. 
These discussions should take into account the socio- economic, cultural factors and religious 
beliefs of the adolescent participant and her family. The investigator should also discuss the management of the pregnancy test results with the subject and her parents/custodians. The 
privacy of the subject should be considered in accordance with the local law and ethics. 
Additional pregnancy tests may be performed at the investigator’s discretion d uring the study. 
Subjects becoming pregnant must be discontinued from study drug. However, a subject may 
choose to remain in the study should she become pregnant, and be followed in the treatment - 
free follow -up period as described in Table 6 -1, Table 6 -2. 
Female subjects of child -bearing potential who do not agree to abstinence  and who are or might 
become sexually  active must be informed of the need to prevent pregnancy, by using effective 
methods of contraception during dosing of study treatment and for a minimum of 16 weeks after stopping study treatment or longer if local label requires it (eg in EU 20 weeks). 
Details on contraception methods can be found in the Exclusion criteria,  Section 4.2 . 
It is recommended that the decision on the contraceptive method should be reviewed at least 
every 3 months to evaluate the individual need and compatibility of the method chosen. 
6.5.9 Appropriateness of safety measurements  
The safety  measures used in this study  are reliable  and relevant  standard  measures for a biologic 
immunomodulating agent in psoriasis. 
6.6 Other  assessments  
6.6.1 Clinical  Outcome Assessments (COAs)  
6.6.1.1 Subject/Patient Reported Outcomes (PRO)  
The impact of psoriasis on various aspects of subject’s health -related quality of life (HRQoL) 
will be assessed by Children’s Dermatology Life Quality Index (CDLQI).  
The Children’s Dermatology Life Quality Index ( Lewis -Jones and Finlay 1995) is a 10 -item 
general dermatology  disability  index designed to assess health -related  quality  of life in pediatric 
subjects aged 4 to 16 years. It is self -explanatory and may be completed by the child with 
assistance from parents or caregivers as necessary. The 10 questions cover six areas of daily 
activities including symptoms and feelings, leisure, school o r holidays, personal relationships, 
sleep and treatment. The questions are based on the preceding week to permit accurate recall.  

Novartis  Confidential  Page  61 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Each  question is answered  on a 4-point Likert  scale scored  from  0 to 3. These are added  to give 
a minimum sc ore of 0 and maximum score of 30. A higher CDLQI score indicates greater 
degree of QoL impairment.  
CDLQI  is available  in two versions, text only and text with cartoons. The text only version will 
be used in this study. The mean completion time of the text version is 120 seconds. 
This questionnaire should be completed  in the language the subject is most  familiar  with before 
any other clinical assessments,  
All subjects will complete  the PRO questions via an electronic  tablet.  The questionnaire should 
be completed by the subject with the help of parent/custodian if and as needed. The site staff 
may help understand the questions, as necessary. The subject should be given sufficient space 
and time to complete  the questionnaire. If subject  experiences  any difficulties  with submission 
after they complete  the PROs,  the study staff should assist  with  submitting  the PRO responses. 
Attempts  should be made  to collect  responses to all PROs  for all subjects,  including from  those 
who prematurely discontinue prior to the study evaluation completion visit, however, if subjects/subjects refuse to  complete  PROs,  this should be documented in  study source records. 
Subject’s refusal to complete study PROs are not protocol deviations. 
The study coordinator should check the questionnaire for completeness and encourage the 
subject to complete any missing responses before the clinical examination. Missing data will not be imputed. 
The CDLQI questionnaire will be completed by  the subject as indicated in  Table 6 -1, Table 6-  
2. CDLQI  will no longer  be completed, once the subjects reach  18 years of age.  
During the COVID-19 pandemic or similar major  health  care disruption that limits  or prevents 
on-site study visits, CDLQI questionnaire data may be collected remotely (e.g. via telephone 
interview of the subject) by qualified site personnel. This will depend on local regulations, 
technical capabilities and followi ng any applicable training in the required process. 
Documentation of the procedure should follow the vendor emergency manual directives. 
Completed  questionnaires will be reviewed  and examined  by the investigator,  before the clinical 
examination,  for responses that may  indicate  potential adverse  events (AEs)  or serious adverse 
events (SAEs). The investigator should review not only the responses to the questions in the 
questionnaires but also for any unsolicited comments written by the subject. If AEs or SAEs are confirmed, then the physician must record the events as per instructions given in Section  
7.1 and S
ection  7.2 of the protocol.  
6.6.1.2 Performance Outcomes (PerfO) 
Not applicable  
6.6.1.4  Proxy Reported Outcomes  
Not applicable  
6.6.2 Resource utilization  
Not applicable  

Novartis  Confidential  Page  62 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
6.6.3 Pharmacokinetics  
At all study  sites, blood samples will be collected for pharmacokinetics (PK) at the scheduled 
visits as indicated in Table 6 -1, Table 6 -2. 
Pharmacokinetic samples will be obtained for all subjects.  For a detailed  description of the 
blood sampling schema, including time points, refer to the Blood Log in Appendix 2. 
All blood samples  will be taken  by direct  venipuncture in a forearm  vein. 
PK sample handling,  labeling and shipment  instructions  
Blood samples (1 mL,) will be collected into SST tubes. The blood sample will be allowed to 
clot over a minimum of 30 minutes at room temperature prior to harvesting of the serum. The 
serum will be obtained by centrifugation at approximately  2500 rpm for 1 0 minutes, or within 
sufficient time and speed to allow formation of a clear supernatant layer. Serum samples will be split into 2 aliquots (polypropylene tubes) and then stored  (within  30 min of serum  collection 
by centrifugation) at -20°C or -70°C (approximately)  prior to shipment to the central  laboratory. 
Shipment of stored aliquots from the site to the central lab should be on a pre -specified basis. 
To the extent possible, the site should send each aliquot of a sample to the central laboratory separately. The central lab will ship aliquots of the samples on dry ice to the analytical laboratory  as per agreement  with Novartis. PK samples will only be disposed of after approval 
by the Sponsor. 
The actual  date and time of sample collection  will be entered  on the appropriate  CRF  page.  
Laboratory manuals will be provided by the central laboratory with detailed information on 
sample collection, sample handling and shipment. 
Tubes and labels  will be provided by the central  laboratory  with  study/sample type and sample 
number preprinted on the label. Further details on labeling of the pharmacokinetic samples can be found in Appendix 2  of the 
protocol.  
PK sample  stability  
Secukinumab is stable in serum  samples for at least 12 months at -20°C or 32 months at -80°C.  
6.6.4 Other  biomarkers  
Not applicable 
 
Safety monitoring  
7.1 Adverse  events  
An adverse event (AE) is any untoward medical occurrence (eg, any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with th e use of a medicinal (investigational) product.  

Novartis  Confidential  Page  63 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.  
The occurrence of adverse events must be sought by non- directive  questioning of the subject at 
each visit or scheduled phone/virtual contact during the study. Adverse events also may be detected  when  they are volunteered by the subject during or  between  visits  or through physical 
examinati on findings, laboratory test findings, or other assessments. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:  
• they induce clinical signs or symptoms, 
• they are considered clinically  significant,  
• they require therapy.  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseli ne or the previous visit, or values which are considered to be non- typical in subject with 
underlying disease. Investigators have the responsibility for managing the safety of individual 
subject and identifying adverse events.  Alert ranges for laboratory  and other  test abnormalities 
are included in Appendix 1. 
Adverse events must be recorded in the appropriate CRF capturing AEs under the signs, 
symptoms or diagnosis associated with them, accompanied by the following information: 
• the severity  grade  
• mild: usually  transient in nature and generally not interfering with normal activities  
• moderate: sufficiently  discomforting to interfere with normal activities  
• severe:  prevents normal activities  
• its relationship to the study  treatment 
• its duration (start  and end dates)  or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.  
• whether it constitutes  a serious adverse event (SAE  - See Section  7.2 for definition  of 
SAE) and which seriousness criteria have been met.  
• action  taken  regarding  secukinumab treatment  
All adverse events must be treated appropriately. Treatment may include one or more of the 
following:  
• no action taken (eg further observation only)  
• secukinumab treatment  interrupted/withdrawn  
• concomitant medication  or non-drug therapy given 
• non-drug therapy  given 
• subject hospitalized/subject’s  hospitalization  prolonged (see Section  7.2 for definition  of 
SAE)  
• its outcome (not recovered/not resolved;  recovered/resolved;  recovered/resolved with 
sequelae; fatal; or unknown) 

Novartis  Confidential  Page  64 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Once an adverse event is detected, it must be followed until its resolution or until it is judged 
to be permanent, and assessment  must  be made at each visit (or more  frequently, if necessary) 
of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome.  
Worsening of psoriasis in this study is evaluated via the use of PASI, IGA mod 2011 and CDLQI  assessments and is not expect
 ed to be captured  as an AE in the eCRF.  Exceptions 
include cases when a) a new type of psoriasis is diagnosed eg guttate psoriasis) or b) the worsening of psoriasis is so severe that a qualitatively different status is reached.  
Informa
tion about c ommon side effects already known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the subject informed consent and should be discussed with the subject during the study as needed. Any new i nformation regarding the safety profile of the medicinal product that is identified 
between IB updates will be communicated as appropriate, for example, via an IN or an Aggregate Safety  Finding. New information  might require an update to the informed  consent 
and has then to be discussed with the subject. 
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject,  or the subject’s personal physician, believes might 
reasonably  be related  to study treatment.  This information  must  be recorded  in the investigator’s 
source documents; however, if the AE meets the criteria of an SAE, it must be reported to Novartis.  
7.2 Serious adverse  events 
7.2.1 Definition of SAE 
An SAE is d efined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s),  symptom(s) or medical  conditions(s)) which  meets any one of the following 
criteria: 
• is fatal or life-threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth  defect  
• requires in-subject hospitalization or prolongation of existing  hospitalization, unless 
hospitalization is for:  
• routine  treatment or monitoring  of the studied indication, not associated  with any 
deterioration in condition 
• elective  or pre-planned treatment  for a pre-existing condition that is unrelated  to the 
indication under study and has not worsened since signing the informed consent 
• treatment on an emergency  out-subject  basis for an event not fulfilling  any of the 
definitions of a SAE given above and not resulting in hospital admission 
• social  reasons and respite  care in the absence of any deterioration  in the subject’s 
general condition 
• is medically  signif icant,  eg defined as an event that jeopardizes the subject  or may require 
medical or surgical intervention.  

Novartis  Confidential  Page  65 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to Annex IV, ICH-E2D Guideline). 
Medical  and scientific  judgment should be exercised  in deciding whether other situations  should 
be considered serious reactions,  such as important  medical  events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention  to prevent one of the other outcomes listed  above. Examples of such events 
are intensive treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result  in hospitalization  or development of dependency or 
abuse (please refer to Annex IV, ICH -E2D Guideline). 
Any suspected  transmission  via a medicinal product of an infectious  agent  is also considered  a 
serious adverse reaction.  
7.2.2 SAE reporting  
To ensure patient safety, every SAE, regardless of causality, occurring after the patient has provided informed consent and until 20 weeks after last dose was taken or until 30 days after the last study  visit (whichever is later) must  be reported  to Novartis  within  24 hours of learning 
of its occurrence. Any SAE reported until 20 weeks after last dose was taken or until End of study visit (whichever is later) must be recorded in the AE eCRF. SAEs beyond that date will 
only be recorded in the Novartis DS&E database. 
Any SAEs experienced after 30 days from end of study visit or 20 weeks after last dose was 
taken (whichever is later) should only be reported to Novartis if the investig ator suspects a 
causal  relationship  to study  treatment.  Recurrent  episodes, complications,  or progression of the 
initial  SAE  must be reported  as follow -up to the original episode,  regardless of when  the event 
occurs.  This report must  be submitted  within  24 hours of the investigator receiving  the follow - 
up information. An SAE that is considered completely unrelated to a previously reported one should be reported  separately  as a new event. All  follow -up information  for the SAE  including 
information on complications, progression of the initial SAE and recurrent episodes must be reported as follow -up to the original episode within 24 hours of the investigator receiving the 
follow -up information. An SAE occurring at a different time interval or otherwise considered 
completely  unrelated to a previously reported one must be reported separately  as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must assess the relationship of each SAE to study treatment, 
complete the SAE Report Form in English, and submit the completed form within 24 hours to Novartis.  Detail ed instructions  regarding the submission process and requirements  for signature 
are to be found in the investigator folder provided to each site.  
Follow-up information  is submitted  as instructed  in the investigator  folder. Each  re-occurrence, 
complication, or progression of  the original  event must  be reported  as a follow -up to that event 
regardless of when  it occurs.  The follow-up information  should describe whether the event has 

Novartis  Confidential  Page  66 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
resolved  or continues, if and how it was treated,  and whether the patient continued or withdrew 
from study participation.  
If the SAE  is not previously  documented in the Investigator’s  Brochure or Package Insert  (new 
occurrence)  and is thought to be related  to the study  treatment  a Drug  Safety  and Epidemiology 
Department  associate may urgently require further information  from  the investigator  for health 
authority reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same st udy treatment that this SAE has been 
reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and 
reported to the competent authorities and relevant ethics committees in accordance with EU 
Guidance 2011/C 172/01 or as per nationa l regulatory  requirements in participating countries.  
Note: SAEs must be reported to Novartis within 24 hours of the investigator learning of its occurrence/receiving follow -up information. 
7.3 Liver  safety  monitoring  
Not Applicable.  
 
7.4 Renal  safety monitoring 
Not Applicable.  
7.5 Reporting of study treatment  errors  including misuse/abuse 
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately 
used not in accordance with the protocol. 
Abuse  corresponds  to the persistent  or sporadic, intentional  excessive use  of a medicinal  product, 
which is accompanied b y harmful physical or psychological effects.  
Study treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the appropriate CRF,  irrespective of whether or not associated  with an AE/SAE and reported to 
Safety only if assoc iated with an SAE. Misuse or abuse will be collected and reported in the 
safety database irrespective of it being associated with an AE/SAE.  
Table 7-1 Guidance for capturing the study treatment errors  including 
misuse/abuse  
Treatment error 
type Document in CRF 
(Yes/No)  Document in AE 
eCRF  Complete  SAE form  
Unintentional  study 
treatment error  Yes Only if associated with 
an AE  Only if associated with an 
SAE 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE 

Novartis  Confidential  Page  67 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
7.6 Pregnancy reporting 
To ensure subject  safety,  each  pregnancy occurring after signing the informed  consent  must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth  defects,  congenital abnormalities,  or maternal 
and/or newborn complications. 
Pregnancy should be recorded on the Pharmacovigilance Pregnancy Form and reported by the 
investigator to the local Novartis Drug Safety and Epidemiology Department.  Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatment.  
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported 
on a SAE form. 
 
Data review  and database management  
8.1 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis representative will review the protocol and data capture requirements (eCRFs) with the investigators and their staff. During the study, Novartis employs several methods of ensuring protocol and Good Clinical Practice (GCP) compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of subject records, the accuracy  of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, 
the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. Continuous remote monitoring of each site’s data may be 
performed by a centralized Novartis CRA organization. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational para meters, and 
provide reports to Novartis Clinical Teams to assist with trial oversight.  
The investigator must maintain source documents for each subject in the study, consisting of case and visit notes (hospital or clinic medical records) containing demogra phic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the subject's file. (Data  not requiring a separate written  record  will be defined  before study start and 
will be recorded directly on the CRFs). The investigator must also keep the original informed consent form signed by the subject (a signed copy is given to the subject). 
The investigator must  give the monitor a ccess to all relevant  source documents to confirm their 
consistency  with the data capture and/or data entry. Novartis monitoring standards require full 
verification  for the presence  of informed  consent, adherence to the inclusion/exclusion criteria, 
docume ntation of SAEs, and of data that will be used for all primary variables. Additional 
checks of the consistency of the source data with the CRFs are performed according to the 
study- specific monitoring plan. No information in source documents about the iden tity of the 
subjects/subjects will be disclosed.  

Novartis  Confidential  Page  68 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
8.2 Data  collection  
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRFs) using fully validated secure web -enabled software that conforms 
to US CFR 21 Part 11 requirements. Designated investigator site staff w ill not be given access 
to the system until they have been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by generating appropriate error messages, allow the data to be confirmed or corrected online by the designated investigator site staff. The Investigator must certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After database lock, the investigator will receive copies of the subject data f or archiving at the 
investigational site.  
Designated  sites and investigator staff will enter  the data required  by the protocol into the EDC 
system.  Designated  investigator site  staff  will not be given  access to the system  until they  have 
been trained.  
Automatic validation procedures within the system check for data discrepancies during and after data entry and, by generating appropriate error messages, allow the data to be confirmed or corrected online by the designated investigator s ite staff. The Investigator must certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After database lock, the investigator will receive copies of the subject data for archiving at the investigational site.  
8.3 Database management  and quality  control 
Novartis personnel will review the data entered by investigational staff for completeness and 
accuracy. Electronic data queries stating the nature of the problem and requesting clarification 
will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff is required to respond promptly to queries and 
to make any necessary changes to the data.  
Concomitant medications entered into the database wil l be coded using the Word Health 
Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non -drug therapies and adverse 
events will be coded using the Medical dictionary for r egulatory activities (MedDRA) 
terminology.  
Laboratory samples will be processed centrally and the results will be sent electronically to Novartis.  
ECG readings will be processed  centrally  and the results will be sent electronically  to Novartis.  
Randomization codes and data about all study drug dispensed to the subject and all dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The data will be s ent electronically 
to Novartis. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been  completed  and the database  has been  declared  to be complete  and accurate,  it will be 

Novartis  Confidential  Page  69 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
locked. Any changes to t he database after that time can only be made after written agreement 
by Novartis Development management. 
8.4 Data  Monitoring  Committee  
An external  data monitoring committee  (DMC)  will be appointed to monitor the safety  of the 
study subjects. 
Details regarding  the DMC process,  responsibilities  and membership  will be available,  as 
needed, in the relevant secukinumab DMC charter.  
8.5 Adjudication  Committee  
Not required.  
 
Data analysis  
Treatment  groups for analyses will be presented  as shown in Table  9-1. 
Table 9-1 Treatment groups for analyses  
 
Weight  Category  Low dose  secukinumab  High dose  secukinumab  
<25kg  75mg  75mg  
25-<50kg  75mg  150mg  
≥50kg  150mg  300mg  
Any data analysis carried  out independently by the investigator should be submitted  to Novartis 
before publication or presentation. 
9.1 Analysis  sets 
The following analysis sets will be used in this trial: 
Randomized set: The randomized set will be defined as all subjects who were randomized at 
baseline visit.  Unless otherwise  specified,  subjects with missing  informed  consent form  as well 
as misrandomized subjects will be excluded from the randomized set.  
Misrandomized  subj ects are subjects who are screen -failures,  but have been  randomized by the 
investigator before eligibility was finally assessed, however have not been treated. If subjects were re -screened and successfully randomized, they will be included in the randomized set 
according to the treatment assigned in the last randomization.  
Full analysis set (FAS):  The FAS will be comprised  of all subjects from  the randomized  set to 
whom study treatment has been assigned. Following the intent -to-treat principle, subjects will 
be analyzed  according  to the treatment assigned  to at randomization. If the actual  randomization 
stratum is different to the assigned stratum in IRT, the actual stratum will be used in analyses. The subjects with severe GCP violation will not be included in the FAS. 
Of note, subjects excluded  from the randomized set will be excluded  from the FAS.  
Safety set : The safety set will include all subjects who took at least one dose of study drug 
during the treatment period. Subjects will be analyzed according to treatment received. 

Novartis  Confidential  Page  70 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
9.2 Subject  demographics  and other  baseline characteristics 
Demographics and baseline characteristics  
Summary statistics will be presented for continuous demographic and baseline characteristics 
variables by treatment group and for all subjects. The number and percentage of subjects in each category will be presented for cat egorical variables by  treatment group.  Summaries will 
be performed on the randomized set unless otherwise specified.  
Medical history  
All conditions entered  as medical  history or current medical  condition at baseline will be coded 
using the MedDRA dictionary. These  will be summarized  by system  organ  class and preferred 
term of the MedDRA dictionary. In addition, summaries for psoriasis specific medical history will be provided. 
9.3 Treatments 
Study treatment  
Exposure to study treatment will be summarized by treatment group on the safety population. The total number  of injections per subject will be summarized in contingency tables and 
summary  statistics  will be performed  on the duration  of exposure. In addition, exposure will be 
categorized to certain time thresholds (eg any exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks,  ≥ 4 
weeks, ≥ 8 weeks, etc.) and the number of subjects within each category will be presented.  
Prior and concomitant medication(s)  
Prior and concomitant medications will be summarized  by treatment group in separate tables.  
Prior medications are defined as  medications taken and stopped prior to date of first dose of 
study treatment.  Any medication  given  at least once between  the day of first dose of randomized 
study treatment and the last day of study visit will be regarded as concomitant medication, including those which started pre-baseline and continued into the treatment period. 
Medications will be presented  in alphabetical  order, by Anatomical Therapeutic Classification  
(ATC)  codes and grouped by anatomical  main  group. Tables will also show  the overall number 
and percentage of subjects receiving at least one medication of a particular ATC code and at 
least one medication in a particular anatomical main group. 
Psoriasis  specific prior medication  will be presented, and summary  will include number of prior 
systemic and biologic psoriasis therapies as well as reason for discontinuation.  
In addition, medical procedures and significant non- drug therapies as coded in MedDRA will 
be summarized.  
9.4 Analysis  of the primary  variable(s)  
This section  will detail  the statistical  analysis of the primary  endpoint. A Bayesian  analysis  has 
been chosen to allow the direct incorporation into the analysis of information about placebo 
response rates from historical data.  

Novartis  Confidential  Page  71 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Data  from four secukinumab  adult placebo -controlled  trials  (CAIN457A2302, CAIN457A2303, 
CAIN457A2308 and CAIN457A2309) and pediatric placebo- controlled trials from other 
biologics ( Paller 2008, Landells et al 2015 ) will be used to obtain a historical placebo control 
through the Bayesian meta -analytic -predictive (MAP) framework (Spiegelhalter et al 2004 , 
Neuenschwander et al. 2010). CAIN457A2310 data will be used if they are reported prior to 
the present study. 
9.4.1 Primary  Variable(s)  
The co-primary  efficacy  variables are PASI  75 response at Week  12 and IGA mod 2011 0 or 1 
response at Week 12. A PASI 75 responder is defined as a subject achieving ≥ 75% 
improvement (reduction) in PASI score compared to baseline. A subject is considered as IGA 
mod 2011 0 or 1 responder if the subject  achieves a score of 0 or 1 and improved from baseline 
by at least 3 points on the IGA mod 2011 scale if the subject enrolled into the study with a score 
of 4 and by at least 2 points on the IGA mod 2011 scale if the subject enrolled into the study with a score of 3. 
9.4.2 Statistical model, hypothesis, and method of analysis  
In order to evaluate the efficacy  of secukinumab after 12 weeks,  a Bayesian  model will be fitted 
to the co- primary endpoint on secukinumab and placebo treatments. A Bayesian method has 
been chosen to allow the direct incorporation into the analysis of information about placebo 
response rates from historical data. These data will be used  to calculate the Bayesian  posterior 
of the log odds ratio between secukinumab and placebo treatment. For the log odds of the secukinumab treatment group a non- informative  prior will be used, whilst the placebo treatment 
group log odds response rate will be represented  though the MAP  prior.  The MAP  prior will be 
derived from  the historical  placebo data using a logistic  Bayesian  mixed -effects model  and will 
represent  the predicted  placebo  log odds response rate for this trial. The analysis will report the 
median  of the means,  the 95% credible interval and the probability  of a positive  treatment  effect 
of the posterior log odds ratio. Comparisons with placebo will be performed for the low and high dose group of secukinumab separately. Analysis  of the co-primary  variables will be based 
on the Full Analysis Set (FAS).  
9.4.3 Handling of mi
 ssing values/censoring/discontinuations  
 
The following imputation  methods will apply  to the missing  data for  analysis up  to Week 52.  
• Pure non- responder imputation (includes Bayesian Primary endpoint analysis at Week 
12): Missing values with respect to response variables based on PASI score and IGA mod 2011 categories were  to be imputed  with non-response regardless to the reason  for 
missing data (e.g. premature  study discontinuation, missed  visit,  administrative  issues). 
Patients  with missing  baseline or those with all post-baseline missing  were  to be imputed 
with non-response (in the secukinumab treatment groups). 
• Descriptive summaries on response variables based on PASI  score and IGA mod 2011 
categories will be imputed with multiple imputations (MI) method as sensitivity 
imputation  method. Multiple  imputation  (MI)  is a simulation  based  approach  where  

Novartis  Confidential  Page  72 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
missing values are replaced by multiple Bayesian draws from the conditional 
distribution of missing data given the observed data and covariates, creating multiple completed data sets.  These completed data sets can then be analyzed using standard 
methods. Within this analysis the PASI score (absolute change from baseline) or IGA 
mod 2011 categories will be imputed and response variables will be derived based on the imputed scores. In the multiple imputation analysis the response status will be imputed based on the individual treatment arm information.  
The following imputation  methods will apply to the missing  data for analysis of the long term 
data beyond Week 52: 
• Response variables based on PASI score and IGA mod 2011 categories will be generally  be presented  as ‘observed case’;  i.e. all available data for each time point 
will be included in the analyses. 
• Summaries  on multiple  imputation  will be provided  as sensitivity  analysis where 
appropriate.  
9.4.4 Sensitivity analyses  
No sensitivity  analysis is planned for the Bayesian primary  endpoint analysis.  
9.5 Analysis  of secondary variables 
The secondary efficacy  variable is PASI 90 response at Week 12 
9.5.1 Efficacy variables  
The key secondary efficacy  endpoint of this study is the proportion of subjects with a PASI 90 
response at Week 12. These data will be analyzed in the same way as the primary endpoint though a Bayesian  framework,  using a Bayesian  mixed -effects model. Efficacy  of secukinumab 
low and high dose compared to historical placebo control will be performed separately. Analyses will be based  on the FAS population, and historical  placebo  data will be incorporation 
into the analysis as before through the MAP framework. 
Missing  data will be handled with the same methods as primary  endpoint analysis.  
9.5.2 Safety variables  
All safety  evaluations will be performed  on the Safety  set. 
Adverse events  
Treatment emergent adverse events will be summarized, and all AEs will be presented in the 
listings.  
AEs will be summarized by presenting, for each treatment group, the number and percentage of subjects having at least one AE, having an AE in each primary  system  organ class and having 
each individual AE (preferred  term).  Summaries  will also be presented  for AEs by severity  and 
for study treatment related AEs.  

Novartis  Confidential  Page  73 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
If a particular AE ‘severity’ is missing, this variable will be listed as missing and treated as 
missing  in summaries.  If a subject  reported  more  than one adverse event with the same preferred 
term, the adverse event with the greatest severity will be presented. If a subject reported more than one adverse event  within  the same  primary  system  organ  class,  the subject will be counted 
only once with the greatest severity at the system organ class level, where applicable.  
Separate summaries  will be provided for death, serious adverse event, other significant adverse 
events leading to discontinuation and adverse events leading to dose adjustment (including study treatment discontinuatio n). A separate AE listing will be produced for subjects who 
reported a treatment deviation, where AEs occurring after treatment deviation will be flagged. 
Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laborator y tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change 
from baseline to each study visit will be presented. These descriptive summaries will be presented  by test group, laboratory  test and treatment  group. Change from baseline will only be 
summarized for subjects with both baseline and post baseline. 
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal laboratory  ranges will be used to evaluate whether  a particular  laboratory  test value was normal, 
low, or high for each visit value relative to whether or not the baseline value was normal, low, or high. These summaries will be presented by laboratory  test and treatment group. Shifts will 
be presented for most extreme val ues post -baseline.  
Immunogenicity  
Immunogenicity  data will be listed.  
Vital signs  
Analysis of vital sign measurements using summary  statistics for the change from baseline for 
each post -baseline visit will be performed. These descriptive summaries will be presented by 
vital sign and treatment group. Change from baseline  will only be summarized  for subjects with 
both baseline and post- baseline values.  
Only “on- treatment” vital signs will be summarized (i.e. assessments within last dose plus 84 
days). All information collected will be listed by subject where on treatment and abnormal values will be flagged.  
The number and percentage of subjects with newl y occurring notable vital sign abnormalities 
will be presented. Further details on the criteria for notable abnormalities will be presented in the Statistical Analysis Plan.  
ECG  
Summary  statistics will be presented for ECG  variables by  visit and treatment group. 

Novartis  Confidential  Page  74 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Physical  development  
Growth  and weight changes will be summarised descriptively.  
 
. 
9.5.3 Resource utilization  
Not applicable  
9.5.4 Health- Related Quality  of Life 
Children’s Dermatology Quality of Life Index (CDLQI) 
Seven scores will be derived from the CDLQI: the total score of each of the six dimensions 
(symptoms and feeling, leisure, school or holidays, personal relationships, sleep, treatment) as well as the total score over all items.  The higher the score,  the more  quality  of life is impaired.  
For each of the seven scores the percentage change from baseline will be derived. Summary statistics will be provided for absolute values as well as for the percentage change by  visit and 
treatment group in contingency tables .(LOCF). 
9.5.5 Pharmacokinetics  
All completed  subjects with quantifiable  pharmacokinetic (PK)  measurements of secukinumab 
will be included in the pharmacokinetic data analysis. Serum concentrations will be expressed 
in mass per volume units. All concentrations below the limit of quantification or missing data will be labeled  as such in the concentration  data listings.  PK concentrations will be summarized 
by visit and treatment group. In addition to mean, standard deviation, coefficient of variation, median  and quartiles,  the geometric  mean  and geometric  coefficient  of variation  and n(log) will 
be presented.  
9.5.6 DNA  
Not Applicable.  
9.5.7 Biomarkers  
Not applicable  
9.5.8 PK/PD  
Not applicable  
9.6 Analysis  of exploratory variables 
The following exploratory  efficacy  endpoints will be assessed:  

Novartis  Confidential  Page  75 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
PASI  75, PASI  90, PASI  100 and IGA 2011 0 or 1 response over time 
Number of subjects with PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response by 
treatment and visit will be presented  in frequency contingency tables and will include absolute 
and relative frequencies.  
Figures  will be  provided displaying responder  rates by  treatment including  confidence  intervals.  
PASI  score over  time 
Summary  statistics  will be provided for absolute PASI  scores as well as for percent  change from 
baselin e by treatment and visit. Figures will also be provided. 
9.7 Interim  analyses  
There  are two planned interim analysis.  An interim ana lysis of the data collected  up until Week 
16, including the co- primary endpoint (at Week 12) will be performed after all subjects have 
completed  either their Week  16 visit or the premature  treatment discontinuation visit.  Another 
interim analysis will be performed when all subjects have completed the Week 52 visit, (or 
premature treatment discontinuation visit). 
Additional analyses  may be performed to support health authority interactions, as necessary.  
Thereafter,  efficacy  and safety  data collected  after Week  52 until the end of study  may be 
reported yearly in separate reports.  
Trial  modifications  are not planned based  on any interim analysis.  
9.8 Sample size calculation  
The sample size for this study is calculated to ensure an adequate number of subjects for PK 
analyses and powered efficacy analyses.  Approximately 80 pediatric subjects from 6 to less 
than 18 years of age at randomization will be recruited. Since a 15% scr eening failure rate is  

Novartis  Confidential  Page  76 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
expected, approximately 95 patients will be screened. The study will aim to recruit at least 60 
subjects with moderate severity and approximately 20 subjects with severe severity. 
Power  calculations were  performed  to support the co-primary  endpoints PASI  75 and IGA 0 or 
1 response at week  12, and secondary  endpoint PASI  90 at week  12, versus placebo  (historical 
control) for the low and high secukinumab dose regimens. Data from four adult placebo - 
controlled  trials  (CAIN457A2302, CAIN457A2303, CAIN457A2308 and CAIN457A2309)  
and pediatric placebo controlled trials ( Paller et al 2008 , Landells et al 2015) were used to 
estimate the historical placebo response rate.  For study CAIN457A2310, a 10% response rate 
was assumed  for PASI  75, IGA 0 or 1 and PASI  90 response for the placebo  group. The power 
calculation was performed  assigning pedia tric data moderate  heterogeneity and adult  trial data 
substantial heterogeneity ( Neuenschwander et al.2010), thus allowing pediatric trial data to be 
given twice the weight compared to adult trial data. All the calculations were performed in the 
R package RBesT (version 1.1) through the meta -analytical -predictive framework 
(Spiegelhalter et  al. 2004, Neuenschwander et al. 2010), and the predicted response rate of the 
placebo group for this study are presented in Table 9 -2 below by endpoint. 
Table 9-2 Predictive placebo response rates  for this study from  model of 
historical data 
 
Endpoint  Mean  Standard 
Deviation  Median  95% CI 
IGA 0 or 1 9% 6% 8% 1-23% 
PASI  75 10% 6% 9% 2-25% 
PASI  90 6% 4% 5% 1-18% 
Requiring that the posterior probability of the log odds ratio difference between placebo and secukinumab exceeds with at least 97.5% zero leads  to a power of approximately  99% for each 
co-primary  endpoint when  assuming  a sample size of 40 pediatric  patients  per treatment  group 
and true response rates of 10% and 65% for PASI  75 and 9% and 45% for IGA mod 2011 0 or 
1 response for placebo and secukinumab respectively. 
For the secondary  endpoint of PASI  90 response, assuming a response rate of 6% and 39% for 
placebo and secukinumab respectively, the power to provide a posterior probability of at least 
97.5% that the PASI 90 response rate on secukinumab is greater than placebo at week 12 is 
approximately 99%. 
The assumed response rates for secuki numab are based on confirmatory efficacy in the adult 
phase III program (CAIN457A2302, CAIN457A2303, CAIN457A2308 and CAIN457A2309). 
 
Ethical  considerations  
10.1 Regulatory and ethical  compliance 
This clinical  study was designed and shall  be implemented,  executed  and reported  in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local  regulations  (including European Directive  2001/20/EC, US CFR 21, and Japanese  

Novartis  Confidential  Page  77 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Ministry of Hea lth, Labor, and Welfare), and with the ethical principles laid down in the 
Declaration of Helsinki.  
10.2 Informed consent  procedures 
Eligible patients may only be included in the study after providing written (witnessed, where 
required by law or regulation), IR B/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been  provided by a legally  acceptable representative(s)  of the patient. 
In cases where  the patient’s  representative gives  consent, the patient  should be informed  about 
the study to the extent possible given his/her understanding. If the patient is capable of doing 
so, he/she should indicate assent  by personally  signing and dating the written  informed  consent 
document or a separate  assent  form.  Informed  consent  must  be obtained before conducting any 
study- specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents. 
Novartis  will provide to invest igators  in a separate  document a proposed informed  consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by the investigator must b e agreed to by Novartis before submission to the IRB/ IEC, and a copy of 
the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
In pediatric  patients  (< 18 years of age) parental permission  and, whenever possible, child  assen t 
is needed instead of the procedure for informed consent used for research involving adults. In 
general, one or both parents or a guardian must be provided with the information ordinarily required for informed  consent,  so that they may decide whether  to allow  the child  to participate, 
and children capable of assent must also express their willingness to participate. These forms will be submitted for IRB/IEC/REB approval.  Subjects who turn 18 years of age during the 
trial must sign the general informed consent form.  
Women of child bearing potential should be informed that taking the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
In the event that Novartis wants  to perform testing  on the samples that are not described  in this 
protocol, additional Institutional Review Board and/or Ethics Committee approval will be 
obtained.  
During the COVID-
 19 pandemic or similar  major  health  care disruption that may challenge the 
ability to obtain a standard written informed consent due t o limitations  that prevent an on- site 
visit, the Investigator may conduct the informed consent discussion remotely (e.g. telephone, videoconference). Guidance issued by local regulatory  bodies on this aspect prevails and must 
be implemented and appropriately documented (e.g. the presence of an impartial witness, sign/dating separate ICFs or assent forms by trial subject/ guardian and person obtaining informed consent, etc). 
In case Home Nursing (other than study treatment administration) is implemented during the 
COVID- 1
9 pandemic or similar major health care disruption, a separate Home Nursing 
informed consent document must be used in addition to the study ICF. 

Novartis  Confidential  Page  78 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
10.3 Responsibilities  of the investigator  and IRB/IEC  
Before  initiating  a trial, the investigator/institution  must obtain approval/favorable opinion from 
the Institutional Review  Board/Independent Ethics  Committee  (IRB/IEC) for the trial protocol, 
informed consent form, consent form updates, subject recruitment procedures (eg, 
advertisements) and any  other written information to be provided to subjects/subjects. Prior to 
study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
Novartis monitors, auditors, Novartis Quality Assurance representatives, designated agents of 
Novartis,  IRBs/IECs,  and regulatory  authorities  as required. If  an inspection of the clinical  site 
is requested by a regulatory authority, the investigator must inform Novartis immediately that this request has been made.  
10.4 Publication of study protocol  and results  
The key design elements of this protocol will be posted in a publicly accessible database such 
as clinicaltrials.gov. In  addition, upon study completion and finalization  of the study report the 
results of this trial will be either submitted  for publication  and/or posted in a publicly accessible 
database of clinical trial results.  
10.5 Quality  Control  and Quality  Assurance 
Novartis maintains a robust Quality Management (QM) system that includes all activities 
involved in quality assurance and quality control, inc luding the assignment of roles and 
responsibilities, the reporting of results, and the documentation of actions and escalation of 
issues identified during the review of quality metrics, incidents, audits and inspections. 
Audits of investigator sites, vendo rs, and Novartis systems are performed by Novartis Pharma 
Auditing and Compliance Quality Assurance, a group independent from those involved in 
conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a kn owledge/risk based approach.  
Audits are conducted to assess GCP  compliance with global and local  regulatory  requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes. 
 
Protocol  adherence 
This protocol defines the  study objectives,  the study  procedures and the data to  be collected  on 
study participants. Additional asses sments  required  to ensure safety  of subjects/subjects should 
be administered  as deemed  necessary  on a case by case basis.  Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any additional procedures for any purpose involving any investigational drugs under the protocol, other than the purpose of the study. If despite this interdiction, data, information, observation would be incidentally collected, the investigator shall immediately disclose it to Novartis and not use it for any  purpose other than the study, except for the appropriate monitoring on study 
participants.  

Novartis  Confidential  Page  79 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC  and health  authorities,  where  required, it cannot be implemented.  
11.1 Protocol amendments  
Any change or addition to the protocol can only be made in  a written  protocol amendment  that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to implementation.  Only  amendments that intended to eliminate  an apparent  immediate  hazard  to 
subjects may be implemented immediately provided the health authoritie s are subsequently 
notified by protocol amendment and the reviewing IRB/IEC is notified. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate  action  required  for the safety  of any subject  included in this study, even  if this action 
represents a deviation from the protocol. In such cases the reporting requirements identified in Section 7 Safety Monitoring must be followed.  

Novartis  Confidential  Page  80 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
References 
References are available upon request  
Augustin M, Reich K, Glaeske G, et al (2010) Co- morbidity  and age-related prevalence of 
psoriasis:  analysis of health  insurance data in Germany. Acta  Derm  Venereol;  90:147–151. 
Beattie PE and Lewis -Jones MS (2006). A comparative study of impairment of quality of life 
in children with skin disease and children with other chronic childhood diseases; Br J 
Dermatol 2006 Jul; 155(1), 145–151. 
Benoit S, Hamm  H (2007) Childhood psoriasi s. Clin Dermatol;  25(6):555– 62. 
Blondell RD, Roster  MB, Dave  KC (1999) Disorders of puberty. Am Fam Physician; 
60(1):209-18, 223-4. Burden AD (1999); Management  of psoriasis  in childhood; CED,  24, 341– 345. 
Comans- Bitter  WM et al (1997) Immunophenotyping of blood lymphocytes in childhood. J 
Pediatr Volume; 130, Number 3: 388-393. 
Committee  for medicinal  products for human use (CHMP),  European Medicines Agency for 
the Evaluation of Medicines for Human Use. (2004) Guideline on clinical investigation of 
medicinal products indicated for the treatment of psoriasis. CHMP/EWP/2454/02 corr 393document. London, UK. 
De Jager  MEA  et al (2009) Epidemiology and prescribed  treatments  in childhood psoriasis:  A 
survey among medical professionals. Journal of Dermatological Treatment; 20:254 –258. 
Doherty SD, Van Voohees A, Lebwohl MG (2008) National psoriasis foundation consensus 
statement  on screening  for latent  tuberculosis  infection  in patients with  psoriasis  treated  with 
systemic and biologic agents. J. Am Acad Dermatol; 59(2): 209–217. 
EMA  (2016) Reflection  paper on extrapolation of efficacy  and safety  in paediatric  medicine 
development http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory 
_and_procedural_guideline/2016/04/WC500204187.pdf  (accessed  on 14 June 2017).  
Farber  EM, Nall ML, (1999); Childhood Psoriasis;  Cutis  1999 Nov; 64(5): 309 - 14. 
FDA (2014). General  Clinical  Pharmacology Considerations for Pediatric  Studies for Drugs 
and Biological Products. https://www.fda.gov/downloads/drugs/guidances/ucm425885.pdf  
(ac
cessed on 14 June 2017). 
Feld,  Corey  H (2007) Hypertension in childhood, Pediatric  in Review:  28: 283- 98. 
Feldman  SR and Krueger GG (2005) Psoriasis assessment  tools  in clinical trials.  Ann Rheum 
Dis; 64(Suppl 2):ii 65 –8. 
Fredriksson T, Pettersson  U (1978) Severe psoriasis – oral therapy  with a new retinoid. 
Dermatologica; 157:238–44. 
Gelfand  JM, Weinstein  R, Porter SB et al (2005). Prevalence and Treatment  of Psoriasis  in the 
United Kingdom: A Population based Study; Arch Dermatol 2005; 141:1537-1541 
Gottlieb A, Griffiths CEM, Ho VC, et al (2005) Oral pimecrolimus in the treatment of 
moderate  to severe chronic plaque type psoriasis:  a double-blind, multicenter,  randomized 
dose- finding trial. Br J Dermatol; 152:1219 -27. 

Novartis  Confidential  Page  81 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Griffiths  CE, Barker  JN (2007) Pathogenesis and clinical features  of psoriasis.  Lancet; 
370:263- 271. 
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (2000). Clinical Investigation of Medicinal Products in the Pediatric Population E11. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4  
/E11_Guideline.pdf (accessed  on 14 June 2017).  
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Hum an Use (2016). Addendum to ICH E11: Clinical Investigation of 
Medicinal Products in the Pediatric Population E11(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/ICH_  
E11_R1_Step_2_25Aug2016_Final.pdf (accessed on 14 June 2017). 
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals fo r Human Use (2003). Post-approval safety data management: definitions 
and standards for expedited reporting (ICH E2D). 2003. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step  
4/E2D_Guideline.pdf. Accessed January 23, 2018. 
Kimball AB et al (2012) Risks  of developing psychiatric disorders in pediatric  patients with 
psoriasis. J Am Acad Dermatol; 674:651-7. 
Kokubu T, et al (2008) Immunolocalization of IL-17A, IL-17B, and Their  Receptors in 
Chondrocytes during Fracture Healing; J Histochem Cytochem; Volume 56(2): 89–95.  
Landells I, Marano C, Hsu MC, et al (2015). Ustekinumab  in adolescent  patients  age 12 to 17 
years with  moderate -to-severe plaque psoriasis:  Results of the randomized phase 3 CADMUS 
study. J Am Acad Dermatol. 73:594-603. 
Langley RG, Krueger GG, Griffiths  CE (2005) Psoriasis:  epidemiology, clinical  features,  and 
quality of life. Ann Rheum Dis; 64:ii18-ii23. 
Leman  J, Burden D (2001) Psoriasis  in children: a guide to its diagnosis and management. 
Paediatr Drugs; 3(9):673–80 Lewis -Jones MS, Finlay  AY. The Children's Dermatology  Life Quality  Index  (CDLQI ): 
initial validation and practical use.  Br J Dermatol 1995; 1326: 942-949. 
Manuel  O, Kumar  D (2008). QuantiFERON- TB Gold  assay  for the diagnosis  of latent 
tuberculosis infection. Expert Rev Mol Diagn; 8(3): 247-56. Neuenschwander  B, Capkun-Niggli G, Branson M, Spiegelhalter DJ (2010) Summarizing 
historical information on controls in clinical trials. Clinical Trials 7, 5 -18. 
Paller AS et al (2008) Etanercept  treatment for children and adolescents with plaque psoriasis. 
N Engl J Med; 358:241-51. 
Pariser  DM, Bagel  J, Gelfand  JM et al (2007) National Psoriasis Foundation Clinical 
Consensus on Disease Severity. Arch Dermatol; 143: 239-242. 
Schwartz GJ, M
 unoz A, Schnei MF et al (2009). New equations to estimate GFR  in children 
with CKD. J Am Soc Nephrol; 20:629-637. 
Silverberg NB (2009); Pediatric psoriasis; Ther Clin Risk Manag 2009;5 849– 856. 

Novartis  Confidential  Page  82 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Spiegelhalter DJ, Abrams  KR, Myles JP (2004) Bayesian  Approaches to Clinical  trials  and 
Healt h-Care Evaluation. Chichester: John Wiley and Sons. 
 
Toll
efson et al (2010) Incidence of psoriasis  in children: a population- based  study. J Am 
Acad Dermatol. 2010 Jun; 62(6):979-87. 
Tollefso n M (2014) Diagnosis and management  of psoriasis in children.  Pediatr  Clin North 
Am; 61(2):261-277. 
Weisman S, Pollack CR, Gottschalk RW (2003). Psoriasis disease severity measures: 
comparing efficacy  of treatments  for severe psoriasis.  J Dermatolog  Treat;  14: 158-165. 
Wu JJ et al (2011) Low prevalence of psoriasis  among children  and adolescents in a large 
multiethnic cohort in southern California.  J Am Acad Dermatol 2011; 65: 957-64. 
Zappel K, Sterry  W, Blume -Peytavi  U (2004) Therapy options for psoriasis in childhood and 
adolescence. JDDG; 2004. 2:329 – 342. 

Novartis  Confidential  Page  83 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Appendix  1: Clinically  notable  laboratory  parameters  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests.  
Unless otherwise indicated, no specific action is pre- defined within this protocol to respond to 
specific abnormal laboratory  values, as it will be decided by  the investigator whether & which 
specific action needs to be taken to respond to any abnormal values, taking into account the overall status of the subject.  
Laboratory values  
Newly occurring selected notable laboratory abnormalities in pediatric patients at the time of the assessment:  
Biochemistry and Urinalysis  
• Alamine  Aminotranferase (ALT)(SGPT):  
>Upper Limit of Normal () 
≥3 x ULN  
≥5 x ULN  
≥8 x ULN  
≥10 x ULN 
• Aspartate Aminotranferase (AST)  (SGOT):  
>ULN  
≥3 x ULN  
≥5 x ULN  
≥8 x ULN  
≥10 x ULN 
• Total  Bilirubin  (TBL)  
>ULN,  
≥1.5xULN,  
≥ 2xULN  
• Alkaline Phosphatase  (ALP)  
>ULN  
≥1.5xULN,  
≥2xULN,  
≥3x ULN 
≥5xULN  
• ALT  and/or AST  >3x-, 5x-, 10x ULN  accompanied  by TBL  >2xULN  
• ALT  or AST  >3x ULN and TBL  >2x-, and ALP  >2 x ULN.  
• ALP  >3x ULN  and TBL >2x ULN 
• Gamma -Glutamyltransferase  (GGT):  
>ULN  

Novartis  Confidential  Page  84 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
≥3 x ULN 
≥5 x ULN 
Hematology  
• Hemoglobin:  
• ≥ 20 g/L decrease  from baseline,  or 
• < 85 g/L for < 16 years of age 
• < 100 g/L for ≥ 16 years of age 
• Absolute neutrophils:  
• Grade  1: <LLN  – 1.5 x 10E9/L  
• Grade  2: <1.5 – 1.0 x 10E9/L  
• Grade  3: <1.0 – 0.5 x 10E9/L  
• Grade 4: <0.5 x 10E9/L  
• Criteria  based  on CTC grades for platelet  count:  
• Grade  1: <LLN  – 75.0 x 10E9/L  
• Grade  2: <75.0 – 50.0 x 10E9/L  
• Grade  3: <50.0 – 25.0 x 10E9/L  
• Grade  4: <25.0 x 10E9/L  
• Criteria  based  on CTC grades for WBC:  
• Grade  1:<LLN  – 3.0 x10E9/L  
• Grade  2:<3.0 – 2.0 x10E9/L  
• Grade  3:<2.0 – 1.0 x10E9/L  
• Grade 4: <1.0 x10E9/L  
• Absolute Lymphocytes: < LLN  
• Absolute Eosinophils: ≥ 1.1 x ULN  
• Absolute Eosinophils: ≥0.45 x 109/L  

Novartis  Confidential  Page  85 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Appendix  2: Blood  collection  log for pharmacokinetics and 
immunogenicity  
Table 14-1 Blood collection log for pharmacokinetics  
 
 
Visit Timepoint  Volume Analyte  Sample 
number1 PK collection 
number  /Dose 
Reference  ID1 
Randomization/Day  1 Pre-dose  1 mL AIN457 for PK 1 1 
Week  4 Pre-dose  1 mL AIN457 for PK 2 2 
Week  12 Pre-dose  1 mL AIN457 for PK 3 3 
Week  13 168 hours2 1 mL AIN457 for PK 4 3 
Week  14 336 hours2 1 mL AIN457 for PK 5 3 
Week  15 504 hours2 1 mL AIN457 for PK 6 3 
Week  16 672 hours2 1 mL AIN457 for PK 7 3 
Week  24 Pre-dose  1 mL AIN457 for PK 8 4 
Week  52 Pre-dose  1 mL AIN457 for PK 9 5 
Week  104 Pre-dose  1 mL AIN457 for PK 10 6 
Week  156 Pre-dose  1 mL AIN457 for PK 11 7 
Week  208 672 hours3 1 mL AIN457 for PK 12 8 
Week  224 3360 hours3 1 mL AIN457 for PK 13 8 
1 If a PK sample is collected at an unscheduled visit, the sample numbers  will follow  the pattern:  1001,  1002,  etc. 
2 Scheduled time points  for sample numbers  4, 5, 6, 7 (168,  336, 504 and 672 hours  post-dose,  respectively) refer 
to the last previous dose given at Week 12 (Dose Reference ID = 3)  
3 Scheduled time points  for sample numbers  12 and 13 (672 and 3360 hours  post-dose,  respectively) refer to the 
last dose given at Week 204 (Dose Reference ID = 8)  
 
Table 14-2 Blood Collection for Immunogenicity  
 
Visit Timepoint  Volume Analyte Immunogenicity 
Sample number1 
Randomization/Day  1 Pre-dose  2 mL anti-AIN457 for IG 501 
Week  16 Pre-dose  2 mL anti-AIN457 for IG 502 
Week  24 Pre-dose  2 mL anti-AIN457 for IG 503 
Week  52 Pre-dose  2 mL anti-AIN457 for IG 504 
Week  104 Pre-dose  2 mL Anti-AIN457 for IG 505 
Week  156 Pre-dose  2 mL Anti-AIN457 for IG 506 
Week  208 672 hours2 2 mL Anti-AIN457 for IG 507 
Week  224 3360 hours2 2 mL anti-AIN457 for IG 508 
1 If an IG sample is collected at an unscheduled visit, the sample numbers  will follow the pattern:  3001,  3002, 
etc. 
2 Scheduled time points  for sample numbers  12 and 13 (672 and 3360 hours  post-dose,  respectively) refer to 
the last dose given at Week 204  

Novartis  Confidential  Page  86 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   

Novartis  Confidential  Page  87 
Protocol  No. CAIN457A2311 Clinical  Trial Protocol  Amendment  (Version  01) Clean   
Appendix  4: Weight  and recommended  blood  volumes  
European Medicines Agency (EMA) recommendations for trial related blood loss (including 
any losses in the maneuver) in pediatric po pulations are that no more than 3% of total blood 
volume should be taken  during a four week  period  and not more  than 1% of total blood volume 
at a single time- point. At a total blood volume estimated at 80 to 90ml per kilogram (kg) body 
weight, this equates to 2.4mL to 2.7mL blood per kg body weight during a four week period, or 0.8mL to 0.9mL blood per kg at any one time. 
These recommend ed volumes must  not be exceeded  for any patient. Please use the information 
below to ensure that the recommended volumes are adhered to. 
Table 16-1 Total blood  volume, 1% and 3% of total blood volume by weight 
assuming 85mL per kg total blood volume 
 
Weight  (Kg) Total  Blood  Volume*  1% Blood  Volume*  3% Blood  Volume*  
 (mL) (mL) (mL) 
5 425 4 12 
10 850 8 24 
15 1275  12 36 
20 1700  17 51 
25 2125  21 63 
30 2550  25 75 
35 2975  29 87 
40 3400  34 102 
45 3825  38 114 
50 4250  42 126 
55 4675  46 138 
60 5100  51 103 
65 5525  55 165 
70 5950  59 177 
75 6375  63 186 
80 6800  68 204 
*all blood volumes  are rounded down 
